<full-text-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/article/dtd" xmlns:bk="http://www.elsevier.com/xml/bk/dtd" xmlns:cals="http://www.elsevier.com/xml/common/cals/dtd" xmlns:ce="http://www.elsevier.com/xml/common/dtd" xmlns:ja="http://www.elsevier.com/xml/ja/dtd" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:sa="http://www.elsevier.com/xml/common/struct-aff/dtd" xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd" xmlns:tb="http://www.elsevier.com/xml/common/table/dtd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><coredata><prism:url>https://api.elsevier.com/content/article/pii/S0223523413000512</prism:url><dc:identifier>doi:10.1016/j.ejmech.2013.01.023</dc:identifier><eid>1-s2.0-S0223523413000512</eid><prism:doi>10.1016/j.ejmech.2013.01.023</prism:doi><pii>S0223-5234(13)00051-2</pii><dc:title>Fragment-based drug design and identification of HJC0123, a novel orally bioavailable STAT3 inhibitor for cancer therapy </dc:title><prism:publicationName>European Journal of Medicinal Chemistry</prism:publicationname><prism:aggregationType>Journal</prism:aggregationtype><pubType>fla</pubtype><prism:issn>02235234</prism:issn><prism:volume>62</prism:volume><prism:startingPage>498</prism:startingpage><prism:endingPage>507</prism:endingpage><prism:pageRange>498-507</prism:pagerange><dc:format>text/xml</dc:format><prism:coverDate>2013-04-30</prism:coverdate><prism:coverDisplayDate>April 2013</prism:coverdisplaydate><prism:copyright>Copyright © 2013 Elsevier Masson SAS. All rights reserved.</prism:copyright><prism:publisher>Elsevier Masson SAS.</prism:publisher><dc:creator>Chen, Haijun</dc:creator><dc:creator>Yang, Zhengduo</dc:creator><dc:creator>Ding, Chunyong</dc:creator><dc:creator>Chu, Lili</dc:creator><dc:creator>Zhang, Yusong</dc:creator><dc:creator>Terry, Kristin</dc:creator><dc:creator>Liu, Huiling</dc:creator><dc:creator>Shen, Qiang</dc:creator><dc:creator>Zhou, Jia</dc:creator><dc:description>
                  Fragment-based drug design (FBDD) is a promising approach for the generation of lead molecules with enhanced activity and especially drug-like properties against therapeutic targets. Herein, we report the fragment-based drug design, systematic chemical synthesis and pharmacological evaluation of novel scaffolds as potent anticancer agents by utilizing six privileged fragments from known STAT3 inhibitors. Several new molecules such as compounds 5, 12, and 19 that may act as advanced chemical leads have been identified. The most potent compound 5 (HJC0123) has demonstrated to inhibit STAT3 promoter activity, downregulate phosphorylation of STAT3, increase the expression of cleaved caspase-3, inhibit cell cycle progression and promote apoptosis in breast and pancreatic cancer cells with low micromolar to nanomolar IC50 values. Furthermore, compound 5 significantly suppressed estrogen receptor (ER)-negative breast cancer MDA-MB-231 xenograft tumor growth in vivo (p.o.), indicating its great potential as an efficacious and orally bioavailable drug candidate for human cancer therapy.
               </dc:description><openaccess>0</openaccess><openaccessArticle>false</openaccessarticle><openaccessType/></openaccesstype><openArchiveArticle>false</openarchivearticle><openaccessSponsorName/></openaccesssponsorname><openaccessSponsorType/></openaccesssponsortype><openaccessUserLicense/></openaccessuserlicense><dcterms:subject>Fragment-based drug design</dcterms:subject><dcterms:subject>Anticancer agents</dcterms:subject><dcterms:subject>Drug discovery</dcterms:subject><dcterms:subject>STAT3</dcterms:subject><dcterms:subject>Breast cancer</dcterms:subject><link href="https://api.elsevier.com/content/article/pii/S0223523413000512" rel="self"/></link><link href="https://www.sciencedirect.com/science/article/pii/S0223523413000512" rel="scidir"/></link></coredata><objects><object ref="fx1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="59" size="13484">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523413000512-fx1.sml?httpAccept=%2A%2F%2A</object><object ref="fx2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="74" size="7943">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523413000512-fx2.sml?httpAccept=%2A%2F%2A</object><object ref="fx3" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="129" size="9950">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523413000512-fx3.sml?httpAccept=%2A%2F%2A</object><object ref="fx4" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="129" size="8747">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523413000512-fx4.sml?httpAccept=%2A%2F%2A</object><object ref="fx5" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="129" size="9227">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523413000512-fx5.sml?httpAccept=%2A%2F%2A</object><object ref="fx6" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="97" size="8412">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523413000512-fx6.sml?httpAccept=%2A%2F%2A</object><object ref="fx7" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="97" size="6292">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523413000512-fx7.sml?httpAccept=%2A%2F%2A</object><object ref="fx8" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="129" size="7665">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523413000512-fx8.sml?httpAccept=%2A%2F%2A</object><object ref="fx9" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="97" size="7334">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523413000512-fx9.sml?httpAccept=%2A%2F%2A</object><object ref="gr1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="131" size="12333">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523413000512-gr1.sml?httpAccept=%2A%2F%2A</object><object ref="gr2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="106" size="9985">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523413000512-gr2.sml?httpAccept=%2A%2F%2A</object><object ref="gr3" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="114" height="164" size="24542">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523413000512-gr3.sml?httpAccept=%2A%2F%2A</object><object ref="gr4" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="183" height="164" size="14642">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523413000512-gr4.sml?httpAccept=%2A%2F%2A</object><object ref="gr5" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="182" height="164" size="19274">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523413000512-gr5.sml?httpAccept=%2A%2F%2A</object><object ref="gr6" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="149" height="164" size="13356">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523413000512-gr6.sml?httpAccept=%2A%2F%2A</object><object ref="sc1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="105" size="9263">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523413000512-sc1.sml?httpAccept=%2A%2F%2A</object><object ref="sc2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="104" size="10714">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523413000512-sc2.sml?httpAccept=%2A%2F%2A</object><object ref="sc3" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="121" size="9493">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523413000512-sc3.sml?httpAccept=%2A%2F%2A</object><object ref="fx1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="500" height="135" size="36496">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523413000512-fx1.jpg?httpAccept=%2A%2F%2A</object><object ref="fx2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="613" height="207" size="23584">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523413000512-fx2.jpg?httpAccept=%2A%2F%2A</object><object ref="fx3" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="156" height="92" size="10784">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523413000512-fx3.jpg?httpAccept=%2A%2F%2A</object><object ref="fx4" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="176" height="104" size="8744">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523413000512-fx4.jpg?httpAccept=%2A%2F%2A</object><object ref="fx5" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="176" height="104" size="9219">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523413000512-fx5.jpg?httpAccept=%2A%2F%2A</object><object ref="fx6" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="176" height="78" size="8343">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523413000512-fx6.jpg?httpAccept=%2A%2F%2A</object><object ref="fx7" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="176" height="78" size="5783">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523413000512-fx7.jpg?httpAccept=%2A%2F%2A</object><object ref="fx8" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="176" height="104" size="7404">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523413000512-fx8.jpg?httpAccept=%2A%2F%2A</object><object ref="fx9" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="176" height="78" size="6904">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523413000512-fx9.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="734" height="438" size="64604">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523413000512-gr1.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="362" height="174" size="18305">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523413000512-gr2.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="379" height="545" size="87945">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523413000512-gr3.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="349" height="313" size="29186">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523413000512-gr4.jpg?httpAccept=%2A%2F%2A</object><object ref="gr5" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="350" height="315" size="37017">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523413000512-gr5.jpg?httpAccept=%2A%2F%2A</object><object ref="gr6" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="323" height="355" size="29151">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523413000512-gr6.jpg?httpAccept=%2A%2F%2A</object><object ref="sc1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="734" height="352" size="40222">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523413000512-sc1.jpg?httpAccept=%2A%2F%2A</object><object ref="sc2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="739" height="351" size="51518">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523413000512-sc2.jpg?httpAccept=%2A%2F%2A</object><object ref="sc3" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="678" height="373" size="38719">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523413000512-sc3.jpg?httpAccept=%2A%2F%2A</object><object ref="fx1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2213" height="599" size="194626">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523413000512-fx1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2713" height="916" size="129341">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523413000512-fx2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx3" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="692" height="409" size="32631">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523413000512-fx3_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx4" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="783" height="461" size="27562">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523413000512-fx4_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx5" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="783" height="462" size="29617">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523413000512-fx5_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx6" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="783" height="348" size="25806">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523413000512-fx6_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx7" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="783" height="348" size="14999">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523413000512-fx7_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx8" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="783" height="461" size="22169">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523413000512-fx8_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx9" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="783" height="348" size="20045">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523413000512-fx9_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3249" height="1938" size="396558">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523413000512-gr1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1604" height="773" size="89034">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523413000512-gr2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1681" height="2418" size="461074">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523413000512-gr3_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1545" height="1386" size="170450">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523413000512-gr4_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr5" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1551" height="1395" size="203626">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523413000512-gr5_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr6" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1433" height="1576" size="130585">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523413000512-gr6_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="sc1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3249" height="1556" size="238291">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523413000512-sc1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="sc2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3270" height="1555" size="318368">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523413000512-sc2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="sc3" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3003" height="1654" size="233366">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523413000512-sc3_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="mmc1" category="standard" type="APPLICATION" multimediatype="Acrobat PDF file" mimetype="application/pdf" size="2901148">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523413000512-mmc1.pdf?httpAccept=%2A%2F%2A</object></objects><scopus-id>84873738776</scopus-id><scopus-eid>2-s2.0-84873738776</scopus-eid><pubmed-id>23416191</pubmed-id><link href="https://api.elsevier.com/content/abstract/scopus_id/84873738776" rel="abstract"/></link><originalText><xocs:doc xsi:schemaLocation="http://www.elsevier.com/xml/xocs/dtd http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd"><xocs:meta xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <xocs:content-family>serial</xocs:content-family>
      <xocs:content-type>JL</xocs:content-type>
      <xocs:cid>271932</xocs:cid>
      <xocs:ssids>
         <xocs:ssid type="alllist">291210</xocs:ssid>
         <xocs:ssid type="subj">291732</xocs:ssid>
         <xocs:ssid type="subj">291789</xocs:ssid>
         <xocs:ssid type="subj">291858</xocs:ssid>
         <xocs:ssid type="subj">291928</xocs:ssid>
         <xocs:ssid type="content">31</xocs:ssid>
      </xocs:ssids>
      <xocs:srctitle>European Journal of Medicinal Chemistry</xocs:srctitle>
      <xocs:normalized-srctitle>EUROPEANJOURNALMEDICINALCHEMISTRY</xocs:normalized-srctitle>
      <xocs:orig-load-date yyyymmdd="20130125">2013-01-25</xocs:orig-load-date>
      <xocs:available-online-date yyyymmdd="20130125">2013-01-25</xocs:available-online-date>
      <xocs:ew-transaction-id>2017-03-12T17:15:57</xocs:ew-transaction-id>
      <xocs:eid>1-s2.0-S0223523413000512</xocs:eid>
      <xocs:pii-formatted>S0223-5234(13)00051-2</xocs:pii-formatted>
      <xocs:pii-unformatted>S0223523413000512</xocs:pii-unformatted>
      <xocs:doi>10.1016/j.ejmech.2013.01.023</xocs:doi>
      <xocs:item-stage>S300</xocs:item-stage>
      <xocs:item-version-number>S300.3</xocs:item-version-number>
      <xocs:item-weight>FULL-TEXT</xocs:item-weight>
      <xocs:hub-eid>1-s2.0-S0223523413X00030</xocs:hub-eid>
      <xocs:timestamp yyyymmdd="20170312">2017-03-12T13:39:40.133355-04:00</xocs:timestamp>
      <xocs:dco>0</xocs:dco>
      <xocs:tomb>0</xocs:tomb>
      <xocs:date-search-begin>20130401</xocs:date-search-begin>
      <xocs:date-search-end>20130430</xocs:date-search-end>
      <xocs:year-nav>2013</xocs:year-nav>
      <xocs:indexeddate epoch="1359072000">2013-01-25T00:00:00Z</xocs:indexeddate>
      <xocs:articleinfo>absattachment articleinfo articletitlenorm authfirstinitialnorm authfirstsurnamenorm cid cids contenttype copyright crossmark dateloaded dateloadedtxt datesearch datesort dateupdated dco docsubtype doctype doi eid ewtransactionid hubeid indexeddate issn issnnorm itemstage itemtransactionid itemweight openaccess openarchive pg pgfirst pglast pii piinorm pubdateend pubdatestart pubdatetxt pubyr sectiontitle sortorder srctitle srctitlenorm srctype ssids alllist content subj subheadings suppl tomb volfirst volissue volumelist webpdf webpdfpagecount yearnav figure table e-component body acknowledge affil appendices articletitle auth authfirstini authfull authkeywords authlast footnotes grantnumber grantsponsor otherkwds primabst pubtype ref specialabst</xocs:articleinfo>
      <xocs:issns>
         <xocs:issn-primary-formatted>0223-5234</xocs:issn-primary-formatted>
         <xocs:issn-primary-unformatted>02235234</xocs:issn-primary-unformatted>
      </xocs:issns>
      <xocs:crossmark is-crossmark="1">true</xocs:crossmark>
      <xocs:vol-first>62</xocs:vol-first>
      <xocs:volume-list>
         <xocs:volume>62</xocs:volume>
      </xocs:volume-list>
      <xocs:suppl>C</xocs:suppl>
      <xocs:vol-iss-suppl-text>Volume 62</xocs:vol-iss-suppl-text>
      <xocs:sort-order>50</xocs:sort-order>
      <xocs:first-fp>498</xocs:first-fp>
      <xocs:last-lp>507</xocs:last-lp>
      <xocs:pages>
         <xocs:first-page>498</xocs:first-page>
         <xocs:last-page>507</xocs:last-page>
      </xocs:pages>
      <xocs:cover-date-orig>
         <xocs:start-date>201304</xocs:start-date>
      </xocs:cover-date-orig>
      <xocs:cover-date-text>April 2013</xocs:cover-date-text>
      <xocs:cover-date-start>2013-04-01</xocs:cover-date-start>
      <xocs:cover-date-end>2013-04-30</xocs:cover-date-end>
      <xocs:cover-date-year>2013</xocs:cover-date-year>
      <xocs:hub-sec>
         <xocs:hub-sec-title>Original articles</xocs:hub-sec-title>
      </xocs:hub-sec>
      <xocs:document-type>article</xocs:document-type>
      <xocs:document-subtype>fla</xocs:document-subtype>
      <xocs:copyright-line>Copyright © 2013 Elsevier Masson SAS. All rights reserved.</xocs:copyright-line>
      <xocs:normalized-article-title>FRAGMENTBASEDDRUGDESIGNIDENTIFICATIONHJC0123ANOVELORALLYBIOAVAILABLESTAT3INHIBITORFORCANCERTHERAPY</xocs:normalized-article-title>
      <xocs:normalized-first-auth-surname>CHEN</xocs:normalized-first-auth-surname>
      <xocs:normalized-first-auth-initial>H</xocs:normalized-first-auth-initial>
      <xocs:item-toc>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>1</xocs:item-toc-label>
            <xocs:item-toc-section-title>Introduction</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>2</xocs:item-toc-label>
            <xocs:item-toc-section-title>Results and discussion</xocs:item-toc-section-title>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.1</xocs:item-toc-label>
               <xocs:item-toc-section-title>Design</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.2</xocs:item-toc-label>
               <xocs:item-toc-section-title>Chemistry</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.3</xocs:item-toc-label>
               <xocs:item-toc-section-title>Biology</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>3</xocs:item-toc-label>
            <xocs:item-toc-section-title>Conclusions</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>4</xocs:item-toc-label>
            <xocs:item-toc-section-title>Experimental</xocs:item-toc-section-title>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.1</xocs:item-toc-label>
               <xocs:item-toc-section-title>Chemistry</xocs:item-toc-section-title>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.1</xocs:item-toc-label>
                  <xocs:item-toc-section-title>2-Cyano-<ce:italic>N</ce:italic>-(1,1-dioxo-1<ce:italic>H</ce:italic>-1λ<ce:sup loc="post">6</ce:sup>-benzo[<ce:italic>b</ce:italic>]thiophen-6-yl)acetamide (<ce:bold>4</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.2</xocs:item-toc-label>
                  <xocs:item-toc-section-title>2-Phenylquinoline-4-carboxylic acid (1,1-dioxo-1<ce:italic>H</ce:italic>-1λ<ce:sup loc="post">6</ce:sup>-benzo[<ce:italic>b</ce:italic>]thiophen-6-yl)amide (<ce:bold>5</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.3</xocs:item-toc-label>
                  <xocs:item-toc-section-title>(<ce:italic>S</ce:italic>)-2-Phenylquinoline-4-carboxylic acid (1-phenylethyl)amide (<ce:bold>8</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.4</xocs:item-toc-label>
                  <xocs:item-toc-section-title>(<ce:italic>S</ce:italic>)-5-Chloro-2-hydroxy-<ce:italic>N</ce:italic>-(1-phenylethyl)benzamide (<ce:bold>9</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.5</xocs:item-toc-label>
                  <xocs:item-toc-section-title>3-(6-Bromopyridin-2-yl)-2-cyano-<ce:italic>N</ce:italic>-(1,1-dioxo-1<ce:italic>H</ce:italic>-1λ<ce:sup loc="post">6</ce:sup>-benzo[<ce:italic>b</ce:italic>]thiophen-6-yl)acrylamide (<ce:bold>10</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.6</xocs:item-toc-label>
                  <xocs:item-toc-section-title>5-Chloro-<ce:italic>N</ce:italic>-(1,1-dioxo-1<ce:italic>H</ce:italic>-1λ<ce:sup loc="post">6</ce:sup>-benzo[<ce:italic>b</ce:italic>]thiophen-6-yl)-2-hydroxybenzamide (<ce:bold>12</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.7</xocs:item-toc-label>
                  <xocs:item-toc-section-title>5-Chloro-<ce:italic>N</ce:italic>-(5-furan-2-yl-[1,3,4]oxadiazol-2-yl)-2-hydroxybenzamide (<ce:bold>13</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.8</xocs:item-toc-label>
                  <xocs:item-toc-section-title>
                     <ce:italic>N</ce:italic>-(1,1-Dioxo-1<ce:italic>H</ce:italic>-1λ<ce:sup loc="post">6</ce:sup>-benzo[<ce:italic>b</ce:italic>]thiophen-6-yl)-2,6-diphenyl-isonicotinamide (<ce:bold>19</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.9</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Acridine-9-carboxylic acid (1,1-dioxo-1<ce:italic>H</ce:italic>-1λ<ce:sup loc="post">6</ce:sup>-benzo[<ce:italic>b</ce:italic>]thiophen-6-yl)amide (<ce:bold>20</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.10</xocs:item-toc-label>
                  <xocs:item-toc-section-title>
                     <ce:italic>N</ce:italic>-(1,1-Dioxo-1<ce:italic>H</ce:italic>-1λ<ce:sup loc="post">6</ce:sup>-benzo[<ce:italic>b</ce:italic>]thiophen-6-yl)isonicotinamide (<ce:bold>21</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.11</xocs:item-toc-label>
                  <xocs:item-toc-section-title>
                     <ce:italic>N</ce:italic>-(1,1-Dioxo-1<ce:italic>H</ce:italic>-1λ<ce:sup loc="post">6</ce:sup>-benzo[<ce:italic>b</ce:italic>]thiophen-6-yl)-2-phenyl-isonicotinamide (<ce:bold>22</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.1.12</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Quinoline-3-carboxylic acid (1,1-dioxo-1<ce:italic>H</ce:italic>-1λ<ce:sup loc="post">6</ce:sup>-benzo[<ce:italic>b</ce:italic>]thiophen-6-yl)amide (<ce:bold>23</ce:bold>)</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>4.2</xocs:item-toc-label>
               <xocs:item-toc-section-title>Biology</xocs:item-toc-section-title>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.2.1</xocs:item-toc-label>
                  <xocs:item-toc-section-title>
                     <ce:italic>In vitro</ce:italic> determination of effects of synthesized compounds on cancer cell proliferation</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.2.2</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Molecular docking studies</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.2.3</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Transient transfection and dual luciferase reporter assays</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.2.4</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Western blot analysis</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.2.5</xocs:item-toc-label>
                  <xocs:item-toc-section-title>
                     <ce:italic>In vivo</ce:italic> antitumor activity assays</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
               <xocs:item-toc-entry ref-elem="ce:sections">
                  <xocs:item-toc-label>4.2.6</xocs:item-toc-label>
                  <xocs:item-toc-section-title>Statistical analysis</xocs:item-toc-section-title>
               </xocs:item-toc-entry>
            </xocs:item-toc-entry>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Conflict of interest</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:acknowledgment">
            <xocs:item-toc-section-title>Acknowledgments</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:appendices">
            <xocs:item-toc-label>Appendix A</xocs:item-toc-label>
            <xocs:item-toc-section-title>Supplementary data</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:bibliography">
            <xocs:item-toc-section-title>References</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
      </xocs:item-toc>
      <xocs:references>
         <xocs:ref-info refid="sref1">
            <xocs:ref-normalized-surname>ZHONG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1994</xocs:ref-pub-year>
            <xocs:ref-first-fp>95</xocs:ref-first-fp>
            <xocs:ref-last-lp>98</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Z</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref2">
            <xocs:ref-normalized-surname>DARNELL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1997</xocs:ref-pub-year>
            <xocs:ref-first-fp>1630</xocs:ref-first-fp>
            <xocs:ref-last-lp>1635</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref3">
            <xocs:ref-normalized-surname>BROMBERG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1999</xocs:ref-pub-year>
            <xocs:ref-first-fp>295</xocs:ref-first-fp>
            <xocs:ref-last-lp>303</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref4">
            <xocs:ref-normalized-surname>BROMBERG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2000</xocs:ref-pub-year>
            <xocs:ref-first-fp>2468</xocs:ref-first-fp>
            <xocs:ref-last-lp>2473</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref5">
            <xocs:ref-normalized-surname>HIRANO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2000</xocs:ref-pub-year>
            <xocs:ref-first-fp>2548</xocs:ref-first-fp>
            <xocs:ref-last-lp>2556</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref6">
            <xocs:ref-normalized-surname>BOWMAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2000</xocs:ref-pub-year>
            <xocs:ref-first-fp>2474</xocs:ref-first-fp>
            <xocs:ref-last-lp>2488</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref7">
            <xocs:ref-normalized-surname>TURKSON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2000</xocs:ref-pub-year>
            <xocs:ref-first-fp>6613</xocs:ref-first-fp>
            <xocs:ref-last-lp>6626</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref8">
            <xocs:ref-normalized-surname>JOHNSTON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>18</xocs:ref-first-fp>
            <xocs:ref-last-lp>26</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref9">
            <xocs:ref-normalized-surname>BUETTNER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-first-fp>945</xocs:ref-first-fp>
            <xocs:ref-last-lp>954</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref10">
            <xocs:ref-normalized-surname>HAURA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>315</xocs:ref-first-fp>
            <xocs:ref-last-lp>324</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref11">
            <xocs:ref-normalized-surname>YU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>41</xocs:ref-first-fp>
            <xocs:ref-last-lp>51</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref12">
            <xocs:ref-normalized-surname>YU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>97</xocs:ref-first-fp>
            <xocs:ref-last-lp>105</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref13">
            <xocs:ref-normalized-surname>DARNELL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>595</xocs:ref-first-fp>
            <xocs:ref-last-lp>596</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref14">
            <xocs:ref-normalized-surname>DARNELL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-first-fp>740</xocs:ref-first-fp>
            <xocs:ref-last-lp>749</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref15">
            <xocs:ref-normalized-surname>YU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>798</xocs:ref-first-fp>
            <xocs:ref-last-lp>809</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref16">
            <xocs:ref-normalized-surname>GERMAIN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>5665</xocs:ref-first-fp>
            <xocs:ref-last-lp>5669</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref17">
            <xocs:ref-normalized-surname>COSTANTINO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>834</xocs:ref-first-fp>
            <xocs:ref-last-lp>843</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref18">
            <xocs:ref-normalized-surname>SIDDIQUEE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>254</xocs:ref-first-fp>
            <xocs:ref-last-lp>267</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref19">
            <xocs:ref-normalized-surname>SCHINDLER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-first-fp>1133</xocs:ref-first-fp>
            <xocs:ref-last-lp>1137</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref20">
            <xocs:ref-normalized-surname>TURKSON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2001</xocs:ref-pub-year>
            <xocs:ref-first-fp>45443</xocs:ref-first-fp>
            <xocs:ref-last-lp>45455</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref21">
            <xocs:ref-normalized-surname>MATSUNO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>371</xocs:ref-first-fp>
            <xocs:ref-last-lp>375</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref22">
            <xocs:ref-normalized-surname>SIDDIQUEE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>7391</xocs:ref-first-fp>
            <xocs:ref-last-lp>7396</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref23">
            <xocs:ref-normalized-surname>SCHUST</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>1235</xocs:ref-first-fp>
            <xocs:ref-last-lp>1242</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref24">
            <xocs:ref-normalized-surname>TURKSON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>1533</xocs:ref-first-fp>
            <xocs:ref-last-lp>1542</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref25">
            <xocs:ref-normalized-surname>TURKSON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>32979</xocs:ref-first-fp>
            <xocs:ref-last-lp>32988</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref26">
            <xocs:ref-normalized-surname>REN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>454</xocs:ref-first-fp>
            <xocs:ref-last-lp>459</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>X</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref27">
            <xocs:ref-normalized-surname>HORIGUCHI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>1592</xocs:ref-first-fp>
            <xocs:ref-last-lp>1599</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref28">
            <xocs:ref-normalized-surname>IWAMARU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>2435</xocs:ref-first-fp>
            <xocs:ref-last-lp>2444</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref29">
            <xocs:ref-normalized-surname>CHEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>85</xocs:ref-first-fp>
            <xocs:ref-last-lp>89</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref30">
            <xocs:ref-normalized-surname>MANDAL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>6126</xocs:ref-first-fp>
            <xocs:ref-last-lp>6141</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref31">
            <xocs:ref-normalized-surname>MANDAL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>3549</xocs:ref-first-fp>
            <xocs:ref-last-lp>3563</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref32">
            <xocs:ref-normalized-surname>YUE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>45</xocs:ref-first-fp>
            <xocs:ref-last-lp>56</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref33">
            <xocs:ref-normalized-surname>DENG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>91</xocs:ref-first-fp>
            <xocs:ref-last-lp>107</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref34">
            <xocs:ref-normalized-surname>ZHAO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>4012</xocs:ref-first-fp>
            <xocs:ref-last-lp>4018</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref35">
            <xocs:ref-normalized-surname>MANKAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>1263</xocs:ref-first-fp>
            <xocs:ref-last-lp>1275</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref36">
            <xocs:ref-normalized-surname>LAVECCHIA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>2359</xocs:ref-first-fp>
            <xocs:ref-last-lp>2375</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref37">
            <xocs:ref-normalized-surname>PAGE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>65</xocs:ref-first-fp>
            <xocs:ref-last-lp>83</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref38">
            <xocs:ref-normalized-surname>DEBNATH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>6645</xocs:ref-first-fp>
            <xocs:ref-last-lp>6668</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref39">
            <xocs:ref-normalized-surname>ERLANSON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>3463</xocs:ref-first-fp>
            <xocs:ref-last-lp>3482</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref40">
            <xocs:ref-normalized-surname>REES</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>660</xocs:ref-first-fp>
            <xocs:ref-last-lp>672</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref41">
            <xocs:ref-normalized-surname>HAJDUK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>6972</xocs:ref-first-fp>
            <xocs:ref-last-lp>6976</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref42">
            <xocs:ref-normalized-surname>BABAOGLU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>720</xocs:ref-first-fp>
            <xocs:ref-last-lp>723</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="bib43a">
            <xocs:ref-normalized-surname>HAJDUK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>211</xocs:ref-first-fp>
            <xocs:ref-last-lp>219</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="bib43b">
            <xocs:ref-normalized-surname>BARELIER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>469</xocs:ref-first-fp>
            <xocs:ref-last-lp>474</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref43">
            <xocs:ref-normalized-surname>LI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>5592</xocs:ref-first-fp>
            <xocs:ref-last-lp>5596</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref44">
            <xocs:ref-normalized-surname>SONG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>4700</xocs:ref-first-fp>
            <xocs:ref-last-lp>4705</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref45">
            <xocs:ref-normalized-surname>BECKER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1998</xocs:ref-pub-year>
            <xocs:ref-first-fp>145</xocs:ref-first-fp>
            <xocs:ref-last-lp>151</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref46">
            <xocs:ref-normalized-surname>TROTT</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>455</xocs:ref-first-fp>
            <xocs:ref-last-lp>461</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>O</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref47">
            <xocs:ref-normalized-surname>CATLETTFALCONE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1999</xocs:ref-pub-year>
            <xocs:ref-first-fp>105</xocs:ref-first-fp>
            <xocs:ref-last-lp>115</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref48">
            <xocs:ref-normalized-surname>BROMBERG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-first-fp>1139</xocs:ref-first-fp>
            <xocs:ref-last-lp>1142</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref49">
            <xocs:ref-normalized-surname>ZHANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>9623</xocs:ref-first-fp>
            <xocs:ref-last-lp>9628</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>X</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref50">
            <xocs:ref-normalized-surname>SHEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>366</xocs:ref-first-fp>
            <xocs:ref-last-lp>377</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Q</xocs:ref-normalized-initial>
         </xocs:ref-info>
      </xocs:references>
      <xocs:refkeys>
         <xocs:refkey3>CHENX2013X498</xocs:refkey3>
         <xocs:refkey4lp>CHENX2013X498X507</xocs:refkey4lp>
         <xocs:refkey4ai>CHENX2013X498XH</xocs:refkey4ai>
         <xocs:refkey5>CHENX2013X498X507XH</xocs:refkey5>
      </xocs:refkeys>
      <xocs:open-access>
         <xocs:oa-article-status is-open-access="0" is-open-archive="0"/></xocs:oa-article-status>
      </xocs:open-access>
      <xocs:attachment-metadata-doc>
         <xocs:attachment-set-type>item</xocs:attachment-set-type>
         <xocs:pii-formatted>S0223-5234(13)00051-2</xocs:pii-formatted>
         <xocs:pii-unformatted>S0223523413000512</xocs:pii-unformatted>
         <xocs:eid>1-s2.0-S0223523413000512</xocs:eid>
         <xocs:doi>10.1016/j.ejmech.2013.01.023</xocs:doi>
         <xocs:cid>271932</xocs:cid>
         <xocs:timestamp>2017-03-12T13:39:40.133355-04:00</xocs:timestamp>
         <xocs:cover-date-start>2013-04-01</xocs:cover-date-start>
         <xocs:cover-date-end>2013-04-30</xocs:cover-date-end>
         <xocs:attachments>
            <xocs:web-pdf>
               <xocs:attachment-eid>1-s2.0-S0223523413000512-main.pdf</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523413000512/MAIN/application/pdf/c8d3db953707eb4b379cbb2e9e4822b0/main.pdf</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523413000512/MAIN/application/pdf/c8d3db953707eb4b379cbb2e9e4822b0/main.pdf</xocs:ucs-locator>
               <xocs:filename>main.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:pdf-optimized>true</xocs:pdf-optimized>
               <xocs:filesize>677908</xocs:filesize>
               <xocs:web-pdf-purpose>MAIN</xocs:web-pdf-purpose>
               <xocs:web-pdf-page-count>10</xocs:web-pdf-page-count>
               <xocs:web-pdf-images>
                  <xocs:web-pdf-image>
                     <xocs:attachment-eid>1-s2.0-S0223523413000512-main_1.png</xocs:attachment-eid>
                     <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523413000512/PREVIEW/image/png/715e6a129d57ec86a59a5a1d556098ff/main_1.png</xocs:ucs-locator>
                     <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523413000512/PREVIEW/image/png/715e6a129d57ec86a59a5a1d556098ff/main_1.png</xocs:ucs-locator>
                     <xocs:filename>main_1.png</xocs:filename>
                     <xocs:extension>png</xocs:extension>
                     <xocs:filesize>59776</xocs:filesize>
                     <xocs:pixel-height>849</xocs:pixel-height>
                     <xocs:pixel-width>656</xocs:pixel-width>
                     <xocs:attachment-type>IMAGE-WEB-PDF</xocs:attachment-type>
                     <xocs:pdf-page-num>1</xocs:pdf-page-num>
                  </xocs:web-pdf-image>
               </xocs:web-pdf-images>
            </xocs:web-pdf>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523413000512-fx1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523413000512/fx1/THUMBNAIL/image/gif/e53c712e22b2ccc4b194009c2118349b/fx1.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523413000512/fx1/THUMBNAIL/image/gif/e53c712e22b2ccc4b194009c2118349b/fx1.sml</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>13484</xocs:filesize>
               <xocs:pixel-height>59</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523413000512-fx2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523413000512/fx2/THUMBNAIL/image/gif/e5854281e1ed5ac5ed6679bc7fa587eb/fx2.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523413000512/fx2/THUMBNAIL/image/gif/e5854281e1ed5ac5ed6679bc7fa587eb/fx2.sml</xocs:ucs-locator>
               <xocs:file-basename>fx2</xocs:file-basename>
               <xocs:filename>fx2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>7943</xocs:filesize>
               <xocs:pixel-height>74</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523413000512-fx3.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523413000512/fx3/THUMBNAIL/image/gif/1d81d89cbd43fb478a50af075a5d3b58/fx3.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523413000512/fx3/THUMBNAIL/image/gif/1d81d89cbd43fb478a50af075a5d3b58/fx3.sml</xocs:ucs-locator>
               <xocs:file-basename>fx3</xocs:file-basename>
               <xocs:filename>fx3.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>9950</xocs:filesize>
               <xocs:pixel-height>129</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523413000512-fx4.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523413000512/fx4/THUMBNAIL/image/gif/338691fb474ce5db64172d37800a8978/fx4.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523413000512/fx4/THUMBNAIL/image/gif/338691fb474ce5db64172d37800a8978/fx4.sml</xocs:ucs-locator>
               <xocs:file-basename>fx4</xocs:file-basename>
               <xocs:filename>fx4.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>8747</xocs:filesize>
               <xocs:pixel-height>129</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523413000512-fx5.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523413000512/fx5/THUMBNAIL/image/gif/846b0a6573bca5397e0cff5ee547d089/fx5.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523413000512/fx5/THUMBNAIL/image/gif/846b0a6573bca5397e0cff5ee547d089/fx5.sml</xocs:ucs-locator>
               <xocs:file-basename>fx5</xocs:file-basename>
               <xocs:filename>fx5.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>9227</xocs:filesize>
               <xocs:pixel-height>129</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523413000512-fx6.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523413000512/fx6/THUMBNAIL/image/gif/532532b4a23530ef3dbca37e3f2ca3c2/fx6.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523413000512/fx6/THUMBNAIL/image/gif/532532b4a23530ef3dbca37e3f2ca3c2/fx6.sml</xocs:ucs-locator>
               <xocs:file-basename>fx6</xocs:file-basename>
               <xocs:filename>fx6.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>8412</xocs:filesize>
               <xocs:pixel-height>97</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523413000512-fx7.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523413000512/fx7/THUMBNAIL/image/gif/e441998f8298829bac99a990973d2687/fx7.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523413000512/fx7/THUMBNAIL/image/gif/e441998f8298829bac99a990973d2687/fx7.sml</xocs:ucs-locator>
               <xocs:file-basename>fx7</xocs:file-basename>
               <xocs:filename>fx7.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>6292</xocs:filesize>
               <xocs:pixel-height>97</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523413000512-fx8.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523413000512/fx8/THUMBNAIL/image/gif/aa743ff577409ae31ec597e9ccc809e6/fx8.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523413000512/fx8/THUMBNAIL/image/gif/aa743ff577409ae31ec597e9ccc809e6/fx8.sml</xocs:ucs-locator>
               <xocs:file-basename>fx8</xocs:file-basename>
               <xocs:filename>fx8.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>7665</xocs:filesize>
               <xocs:pixel-height>129</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523413000512-fx9.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523413000512/fx9/THUMBNAIL/image/gif/ffa7ac33f56b02439eee44df66867cfb/fx9.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523413000512/fx9/THUMBNAIL/image/gif/ffa7ac33f56b02439eee44df66867cfb/fx9.sml</xocs:ucs-locator>
               <xocs:file-basename>fx9</xocs:file-basename>
               <xocs:filename>fx9.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>7334</xocs:filesize>
               <xocs:pixel-height>97</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523413000512-gr1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523413000512/gr1/THUMBNAIL/image/gif/ac2393b75133394c289eb323351ee44a/gr1.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523413000512/gr1/THUMBNAIL/image/gif/ac2393b75133394c289eb323351ee44a/gr1.sml</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>12333</xocs:filesize>
               <xocs:pixel-height>131</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523413000512-gr2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523413000512/gr2/THUMBNAIL/image/gif/a2e10415f8a25b7919f0b7790088640e/gr2.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523413000512/gr2/THUMBNAIL/image/gif/a2e10415f8a25b7919f0b7790088640e/gr2.sml</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>9985</xocs:filesize>
               <xocs:pixel-height>106</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523413000512-gr3.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523413000512/gr3/THUMBNAIL/image/gif/a54acf66f1d043f4fa175eb645b99e5c/gr3.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523413000512/gr3/THUMBNAIL/image/gif/a54acf66f1d043f4fa175eb645b99e5c/gr3.sml</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>24542</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>114</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523413000512-gr4.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523413000512/gr4/THUMBNAIL/image/gif/ea9d1360aba28d2d9d3f31b1cb43351d/gr4.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523413000512/gr4/THUMBNAIL/image/gif/ea9d1360aba28d2d9d3f31b1cb43351d/gr4.sml</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>14642</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>183</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523413000512-gr5.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523413000512/gr5/THUMBNAIL/image/gif/2d7927ab0e2f1840a9fd8830e69d1b04/gr5.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523413000512/gr5/THUMBNAIL/image/gif/2d7927ab0e2f1840a9fd8830e69d1b04/gr5.sml</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>19274</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>182</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523413000512-gr6.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523413000512/gr6/THUMBNAIL/image/gif/55f609a698b5fcb2fcf26e9054557438/gr6.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523413000512/gr6/THUMBNAIL/image/gif/55f609a698b5fcb2fcf26e9054557438/gr6.sml</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>13356</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>149</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523413000512-sc1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523413000512/sc1/THUMBNAIL/image/gif/e2fcf6e8d243b425a11ce399af02dc4a/sc1.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523413000512/sc1/THUMBNAIL/image/gif/e2fcf6e8d243b425a11ce399af02dc4a/sc1.sml</xocs:ucs-locator>
               <xocs:file-basename>sc1</xocs:file-basename>
               <xocs:filename>sc1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>9263</xocs:filesize>
               <xocs:pixel-height>105</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523413000512-sc2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523413000512/sc2/THUMBNAIL/image/gif/236e87f084640241e306ba6a90dadb3c/sc2.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523413000512/sc2/THUMBNAIL/image/gif/236e87f084640241e306ba6a90dadb3c/sc2.sml</xocs:ucs-locator>
               <xocs:file-basename>sc2</xocs:file-basename>
               <xocs:filename>sc2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>10714</xocs:filesize>
               <xocs:pixel-height>104</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523413000512-sc3.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523413000512/sc3/THUMBNAIL/image/gif/21db9ec729677ac97c90bc59f67377c4/sc3.sml</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523413000512/sc3/THUMBNAIL/image/gif/21db9ec729677ac97c90bc59f67377c4/sc3.sml</xocs:ucs-locator>
               <xocs:file-basename>sc3</xocs:file-basename>
               <xocs:filename>sc3.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>9493</xocs:filesize>
               <xocs:pixel-height>121</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523413000512-fx1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523413000512/fx1/DOWNSAMPLED/image/jpeg/76eaa523783f3b0a4ae9acda3346a80f/fx1.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523413000512/fx1/DOWNSAMPLED/image/jpeg/76eaa523783f3b0a4ae9acda3346a80f/fx1.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>36496</xocs:filesize>
               <xocs:pixel-height>135</xocs:pixel-height>
               <xocs:pixel-width>500</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523413000512-fx2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523413000512/fx2/DOWNSAMPLED/image/jpeg/d8c048da8dc7ce8299473c894682ef5d/fx2.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523413000512/fx2/DOWNSAMPLED/image/jpeg/d8c048da8dc7ce8299473c894682ef5d/fx2.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx2</xocs:file-basename>
               <xocs:filename>fx2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>23584</xocs:filesize>
               <xocs:pixel-height>207</xocs:pixel-height>
               <xocs:pixel-width>613</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523413000512-fx3.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523413000512/fx3/DOWNSAMPLED/image/jpeg/942dd0bca4bc1d9afc7f75d2da7943f5/fx3.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523413000512/fx3/DOWNSAMPLED/image/jpeg/942dd0bca4bc1d9afc7f75d2da7943f5/fx3.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx3</xocs:file-basename>
               <xocs:filename>fx3.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>10784</xocs:filesize>
               <xocs:pixel-height>92</xocs:pixel-height>
               <xocs:pixel-width>156</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523413000512-fx4.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523413000512/fx4/DOWNSAMPLED/image/jpeg/b29548b93d33cc3b5ea7176944531a4a/fx4.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523413000512/fx4/DOWNSAMPLED/image/jpeg/b29548b93d33cc3b5ea7176944531a4a/fx4.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx4</xocs:file-basename>
               <xocs:filename>fx4.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>8744</xocs:filesize>
               <xocs:pixel-height>104</xocs:pixel-height>
               <xocs:pixel-width>176</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523413000512-fx5.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523413000512/fx5/DOWNSAMPLED/image/jpeg/63c04b69f0701db83d08d883dee2de38/fx5.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523413000512/fx5/DOWNSAMPLED/image/jpeg/63c04b69f0701db83d08d883dee2de38/fx5.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx5</xocs:file-basename>
               <xocs:filename>fx5.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>9219</xocs:filesize>
               <xocs:pixel-height>104</xocs:pixel-height>
               <xocs:pixel-width>176</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523413000512-fx6.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523413000512/fx6/DOWNSAMPLED/image/jpeg/77e0459031a0b16f1817d79eb0190245/fx6.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523413000512/fx6/DOWNSAMPLED/image/jpeg/77e0459031a0b16f1817d79eb0190245/fx6.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx6</xocs:file-basename>
               <xocs:filename>fx6.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>8343</xocs:filesize>
               <xocs:pixel-height>78</xocs:pixel-height>
               <xocs:pixel-width>176</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523413000512-fx7.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523413000512/fx7/DOWNSAMPLED/image/jpeg/3264b943991c43f2456cf90419895760/fx7.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523413000512/fx7/DOWNSAMPLED/image/jpeg/3264b943991c43f2456cf90419895760/fx7.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx7</xocs:file-basename>
               <xocs:filename>fx7.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>5783</xocs:filesize>
               <xocs:pixel-height>78</xocs:pixel-height>
               <xocs:pixel-width>176</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523413000512-fx8.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523413000512/fx8/DOWNSAMPLED/image/jpeg/3d4644947b182293a2047660c8dc1195/fx8.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523413000512/fx8/DOWNSAMPLED/image/jpeg/3d4644947b182293a2047660c8dc1195/fx8.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx8</xocs:file-basename>
               <xocs:filename>fx8.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>7404</xocs:filesize>
               <xocs:pixel-height>104</xocs:pixel-height>
               <xocs:pixel-width>176</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523413000512-fx9.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523413000512/fx9/DOWNSAMPLED/image/jpeg/31e3e4a127eaa68d2cb219da40131192/fx9.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523413000512/fx9/DOWNSAMPLED/image/jpeg/31e3e4a127eaa68d2cb219da40131192/fx9.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx9</xocs:file-basename>
               <xocs:filename>fx9.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>6904</xocs:filesize>
               <xocs:pixel-height>78</xocs:pixel-height>
               <xocs:pixel-width>176</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523413000512-gr1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523413000512/gr1/DOWNSAMPLED/image/jpeg/53b4a1c49b3e18dc4cca1059976143a3/gr1.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523413000512/gr1/DOWNSAMPLED/image/jpeg/53b4a1c49b3e18dc4cca1059976143a3/gr1.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>64604</xocs:filesize>
               <xocs:pixel-height>438</xocs:pixel-height>
               <xocs:pixel-width>734</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523413000512-gr2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523413000512/gr2/DOWNSAMPLED/image/jpeg/36cfc1a111605680134dc8b67f450b1f/gr2.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523413000512/gr2/DOWNSAMPLED/image/jpeg/36cfc1a111605680134dc8b67f450b1f/gr2.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>18305</xocs:filesize>
               <xocs:pixel-height>174</xocs:pixel-height>
               <xocs:pixel-width>362</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523413000512-gr3.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523413000512/gr3/DOWNSAMPLED/image/jpeg/6a5180fc50cdedf11de157ccfc0863e8/gr3.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523413000512/gr3/DOWNSAMPLED/image/jpeg/6a5180fc50cdedf11de157ccfc0863e8/gr3.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>87945</xocs:filesize>
               <xocs:pixel-height>545</xocs:pixel-height>
               <xocs:pixel-width>379</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523413000512-gr4.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523413000512/gr4/DOWNSAMPLED/image/jpeg/d02672cdbe252b49e72848dc59edf1f5/gr4.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523413000512/gr4/DOWNSAMPLED/image/jpeg/d02672cdbe252b49e72848dc59edf1f5/gr4.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>29186</xocs:filesize>
               <xocs:pixel-height>313</xocs:pixel-height>
               <xocs:pixel-width>349</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523413000512-gr5.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523413000512/gr5/DOWNSAMPLED/image/jpeg/18696a1c41620495d305aea96ffdd127/gr5.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523413000512/gr5/DOWNSAMPLED/image/jpeg/18696a1c41620495d305aea96ffdd127/gr5.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>37017</xocs:filesize>
               <xocs:pixel-height>315</xocs:pixel-height>
               <xocs:pixel-width>350</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523413000512-gr6.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523413000512/gr6/DOWNSAMPLED/image/jpeg/262446d9952ac56c78aceeb835e1ae87/gr6.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523413000512/gr6/DOWNSAMPLED/image/jpeg/262446d9952ac56c78aceeb835e1ae87/gr6.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>29151</xocs:filesize>
               <xocs:pixel-height>355</xocs:pixel-height>
               <xocs:pixel-width>323</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523413000512-sc1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523413000512/sc1/DOWNSAMPLED/image/jpeg/8004f1593550951797b71773930baaa8/sc1.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523413000512/sc1/DOWNSAMPLED/image/jpeg/8004f1593550951797b71773930baaa8/sc1.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc1</xocs:file-basename>
               <xocs:filename>sc1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>40222</xocs:filesize>
               <xocs:pixel-height>352</xocs:pixel-height>
               <xocs:pixel-width>734</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523413000512-sc2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523413000512/sc2/DOWNSAMPLED/image/jpeg/5224af586d3bf732f1b3957c7e60c72a/sc2.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523413000512/sc2/DOWNSAMPLED/image/jpeg/5224af586d3bf732f1b3957c7e60c72a/sc2.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc2</xocs:file-basename>
               <xocs:filename>sc2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>51518</xocs:filesize>
               <xocs:pixel-height>351</xocs:pixel-height>
               <xocs:pixel-width>739</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523413000512-sc3.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523413000512/sc3/DOWNSAMPLED/image/jpeg/5ff981e42014cbffc8904678ec87b763/sc3.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523413000512/sc3/DOWNSAMPLED/image/jpeg/5ff981e42014cbffc8904678ec87b763/sc3.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc3</xocs:file-basename>
               <xocs:filename>sc3.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>38719</xocs:filesize>
               <xocs:pixel-height>373</xocs:pixel-height>
               <xocs:pixel-width>678</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523413000512-fx1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523413000512/fx1/HIGHRES/image/jpeg/0a7e99f65b039608f6563a9424bd3480/fx1_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523413000512/fx1/HIGHRES/image/jpeg/0a7e99f65b039608f6563a9424bd3480/fx1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>194626</xocs:filesize>
               <xocs:pixel-height>599</xocs:pixel-height>
               <xocs:pixel-width>2213</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523413000512-fx2_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523413000512/fx2/HIGHRES/image/jpeg/9741b4f9020250f7a1b4029eb9c013a7/fx2_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523413000512/fx2/HIGHRES/image/jpeg/9741b4f9020250f7a1b4029eb9c013a7/fx2_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx2</xocs:file-basename>
               <xocs:filename>fx2_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>129341</xocs:filesize>
               <xocs:pixel-height>916</xocs:pixel-height>
               <xocs:pixel-width>2713</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523413000512-fx3_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523413000512/fx3/HIGHRES/image/jpeg/779ab5162ec0edd985aa7ac6f631acde/fx3_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523413000512/fx3/HIGHRES/image/jpeg/779ab5162ec0edd985aa7ac6f631acde/fx3_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx3</xocs:file-basename>
               <xocs:filename>fx3_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>32631</xocs:filesize>
               <xocs:pixel-height>409</xocs:pixel-height>
               <xocs:pixel-width>692</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523413000512-fx4_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523413000512/fx4/HIGHRES/image/jpeg/29ad6f8a56410faa5b55ab8f7c6a5551/fx4_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523413000512/fx4/HIGHRES/image/jpeg/29ad6f8a56410faa5b55ab8f7c6a5551/fx4_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx4</xocs:file-basename>
               <xocs:filename>fx4_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>27562</xocs:filesize>
               <xocs:pixel-height>461</xocs:pixel-height>
               <xocs:pixel-width>783</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523413000512-fx5_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523413000512/fx5/HIGHRES/image/jpeg/eefc34e65d04cf9cc793cf18d74fd9c6/fx5_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523413000512/fx5/HIGHRES/image/jpeg/eefc34e65d04cf9cc793cf18d74fd9c6/fx5_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx5</xocs:file-basename>
               <xocs:filename>fx5_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>29617</xocs:filesize>
               <xocs:pixel-height>462</xocs:pixel-height>
               <xocs:pixel-width>783</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523413000512-fx6_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523413000512/fx6/HIGHRES/image/jpeg/53d15907009445208719db619f51d586/fx6_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523413000512/fx6/HIGHRES/image/jpeg/53d15907009445208719db619f51d586/fx6_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx6</xocs:file-basename>
               <xocs:filename>fx6_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>25806</xocs:filesize>
               <xocs:pixel-height>348</xocs:pixel-height>
               <xocs:pixel-width>783</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523413000512-fx7_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523413000512/fx7/HIGHRES/image/jpeg/b51aa5a7303788e888e7f9a3439db01f/fx7_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523413000512/fx7/HIGHRES/image/jpeg/b51aa5a7303788e888e7f9a3439db01f/fx7_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx7</xocs:file-basename>
               <xocs:filename>fx7_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>14999</xocs:filesize>
               <xocs:pixel-height>348</xocs:pixel-height>
               <xocs:pixel-width>783</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523413000512-fx8_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523413000512/fx8/HIGHRES/image/jpeg/37e9e030f1d9e40b4993daf5d9a96b36/fx8_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523413000512/fx8/HIGHRES/image/jpeg/37e9e030f1d9e40b4993daf5d9a96b36/fx8_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx8</xocs:file-basename>
               <xocs:filename>fx8_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>22169</xocs:filesize>
               <xocs:pixel-height>461</xocs:pixel-height>
               <xocs:pixel-width>783</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523413000512-fx9_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523413000512/fx9/HIGHRES/image/jpeg/415a1d5383728bc5fd492a79dd735df5/fx9_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523413000512/fx9/HIGHRES/image/jpeg/415a1d5383728bc5fd492a79dd735df5/fx9_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx9</xocs:file-basename>
               <xocs:filename>fx9_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>20045</xocs:filesize>
               <xocs:pixel-height>348</xocs:pixel-height>
               <xocs:pixel-width>783</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523413000512-gr1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523413000512/gr1/HIGHRES/image/jpeg/ff1a0150f9ac1e0f26bf6e1d04326f0d/gr1_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523413000512/gr1/HIGHRES/image/jpeg/ff1a0150f9ac1e0f26bf6e1d04326f0d/gr1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>396558</xocs:filesize>
               <xocs:pixel-height>1938</xocs:pixel-height>
               <xocs:pixel-width>3249</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523413000512-gr2_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523413000512/gr2/HIGHRES/image/jpeg/91523398673f9e7ad8fc95581517fae9/gr2_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523413000512/gr2/HIGHRES/image/jpeg/91523398673f9e7ad8fc95581517fae9/gr2_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>89034</xocs:filesize>
               <xocs:pixel-height>773</xocs:pixel-height>
               <xocs:pixel-width>1604</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523413000512-gr3_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523413000512/gr3/HIGHRES/image/jpeg/09354428fb98ae624f6d277f4f0f48c6/gr3_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523413000512/gr3/HIGHRES/image/jpeg/09354428fb98ae624f6d277f4f0f48c6/gr3_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>461074</xocs:filesize>
               <xocs:pixel-height>2418</xocs:pixel-height>
               <xocs:pixel-width>1681</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523413000512-gr4_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523413000512/gr4/HIGHRES/image/jpeg/6116e7e68750707d3ab998aeece6c361/gr4_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523413000512/gr4/HIGHRES/image/jpeg/6116e7e68750707d3ab998aeece6c361/gr4_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr4</xocs:file-basename>
               <xocs:filename>gr4_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>170450</xocs:filesize>
               <xocs:pixel-height>1386</xocs:pixel-height>
               <xocs:pixel-width>1545</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523413000512-gr5_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523413000512/gr5/HIGHRES/image/jpeg/d892003d0a8035b698436408e168a677/gr5_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523413000512/gr5/HIGHRES/image/jpeg/d892003d0a8035b698436408e168a677/gr5_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>203626</xocs:filesize>
               <xocs:pixel-height>1395</xocs:pixel-height>
               <xocs:pixel-width>1551</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523413000512-gr6_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523413000512/gr6/HIGHRES/image/jpeg/50ffd69385c5ea5ff5503747466d5cfe/gr6_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523413000512/gr6/HIGHRES/image/jpeg/50ffd69385c5ea5ff5503747466d5cfe/gr6_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>130585</xocs:filesize>
               <xocs:pixel-height>1576</xocs:pixel-height>
               <xocs:pixel-width>1433</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523413000512-sc1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523413000512/sc1/HIGHRES/image/jpeg/046a113c13fde05c325c435539599c5e/sc1_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523413000512/sc1/HIGHRES/image/jpeg/046a113c13fde05c325c435539599c5e/sc1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc1</xocs:file-basename>
               <xocs:filename>sc1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>238291</xocs:filesize>
               <xocs:pixel-height>1556</xocs:pixel-height>
               <xocs:pixel-width>3249</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523413000512-sc2_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523413000512/sc2/HIGHRES/image/jpeg/e4d937a8debbd6e65eeb6544b217fbfe/sc2_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523413000512/sc2/HIGHRES/image/jpeg/e4d937a8debbd6e65eeb6544b217fbfe/sc2_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc2</xocs:file-basename>
               <xocs:filename>sc2_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>318368</xocs:filesize>
               <xocs:pixel-height>1555</xocs:pixel-height>
               <xocs:pixel-width>3270</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523413000512-sc3_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523413000512/sc3/HIGHRES/image/jpeg/35b400a8d1d67c91e2eb9f7031703c63/sc3_lrg.jpg</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523413000512/sc3/HIGHRES/image/jpeg/35b400a8d1d67c91e2eb9f7031703c63/sc3_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>sc3</xocs:file-basename>
               <xocs:filename>sc3_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>233366</xocs:filesize>
               <xocs:pixel-height>1654</xocs:pixel-height>
               <xocs:pixel-width>3003</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523413000512-mmc1.pdf</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S0223523413000512/mmc1/MAIN/application/pdf/1fc13200af07c7c4d03e33b5dd6cb0e5/mmc1.pdf</xocs:ucs-locator>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523413000512/mmc1/MAIN/application/pdf/1fc13200af07c7c4d03e33b5dd6cb0e5/mmc1.pdf</xocs:ucs-locator>
               <xocs:file-basename>mmc1</xocs:file-basename>
               <xocs:filename>mmc1.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:pdf-optimized>false</xocs:pdf-optimized>
               <xocs:filesize>2901148</xocs:filesize>
               <xocs:attachment-type>APPLICATION</xocs:attachment-type>
            </xocs:attachment>
         </xocs:attachments>
      </xocs:attachment-metadata-doc>
   </xocs:meta><xocs:serial-item xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <article xmlns="http://www.elsevier.com/xml/ja/dtd" docsubtype="fla" version="5.1" xml:lang="en">
         <item-info>
            <jid>EJMECH</jid>
            <aid>5955</aid>
            <ce:pii>S0223-5234(13)00051-2</ce:pii>
            <ce:doi>10.1016/j.ejmech.2013.01.023</ce:doi>
            <ce:copyright type="full-transfer" year="2013">Elsevier Masson SAS</ce:copyright>
         </item-info>
         <ce:floats>
            <ce:figure id="fig1">
               <ce:label>Fig. 1</ce:label>
               <ce:caption>
                  <ce:simple-para id="fspara0010" view="all">Chemical structures of representative non-peptidic STAT3 inhibitors.</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr1"/></ce:link>
            </ce:figure>
            <ce:figure id="fig2">
               <ce:label>Fig. 2</ce:label>
               <ce:caption>
                  <ce:simple-para id="fspara0015" view="all">Privileged fragments selected from known STAT3 inhibitors including niclosamide, STX-0119, WP1066, and stattic.</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr2"/></ce:link>
            </ce:figure>
            <ce:figure id="fig3">
               <ce:label>Fig. 3</ce:label>
               <ce:caption>
                  <ce:simple-para id="fspara0020" view="all">Predicted binding mode for compound <ce:bold>5</ce:bold>. (A) Surface of the electrostatic map. (B) Residues of STAT3. Compound <ce:bold>5</ce:bold> is shown in small sticks and in pink color. Hydrogen bonds are indicated by dashed lines. The figures were generated using Pymol. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr3"/></ce:link>
            </ce:figure>
            <ce:figure id="fig4">
               <ce:label>Fig. 4</ce:label>
               <ce:caption>
                  <ce:simple-para id="fspara0025" view="all">Compound <ce:bold>5</ce:bold> (<ce:bold>HJC0123</ce:bold>) inhibited the STAT3 mediated luciferase reporter activity in MDA-MB-231 cells. STAT3 promoter activity was measured using dual luciferase assay with a STAT3 reporter. Promoter activity obtained from DMSO-treated MDA-MB-231 cells was used as control. Error bars represent standard deviation of triplicate wells. Representative experiment from at least 3 independent experiments is shown. RLU: relative luciferase unit.</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr4"/></ce:link>
            </ce:figure>
            <ce:figure id="fig5">
               <ce:label>Fig. 5</ce:label>
               <ce:caption>
                  <ce:simple-para id="fspara0030" view="all">Western blot analysis of biochemical markers for apoptosis induction and inhibition of STAT3 activity by compound <ce:bold>5</ce:bold> (<ce:bold>HJC0123</ce:bold>) in the MDA-MB-231 cell line. Cells were treated with compound <ce:bold>5</ce:bold> for 24 h and 48 h, and levels of STAT3, pSTAT3, cleaved caspase-3 were probed by specific antibodies. β-Actin was used as the loading control.</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr5"/></ce:link>
            </ce:figure>
            <ce:figure id="fig6">
               <ce:label>Fig. 6</ce:label>
               <ce:caption>
                  <ce:simple-para id="fspara0035" view="all">
                     <ce:italic>In vivo</ce:italic> efficacy of compound <ce:bold>5</ce:bold> (<ce:bold>HJC0123</ce:bold>) in inhibiting growth of xenograft tumors (Breast cancer MDA-MB-231) in mice (p.o.).</ce:simple-para>
               </ce:caption>
               <ce:link locator="gr6"/></ce:link>
            </ce:figure>
            <ce:figure id="sch1">
               <ce:label>Scheme 1</ce:label>
               <ce:link locator="sc1"/></ce:link>
            </ce:figure>
            <ce:figure id="sch2">
               <ce:label>Scheme 2</ce:label>
               <ce:link locator="sc2"/></ce:link>
            </ce:figure>
            <ce:figure id="sch3">
               <ce:label>Scheme 3</ce:label>
               <ce:link locator="sc3"/></ce:link>
            </ce:figure>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" id="tbl1" frame="topbot" colsep="0" rowsep="0">
               <ce:label>Table 1</ce:label>
               <ce:caption>
                  <ce:simple-para id="tspara0010" view="all">Effects of newly synthesized compounds <ce:bold>4</ce:bold>, <ce:bold>5</ce:bold>, <ce:bold>8</ce:bold>–<ce:bold>10</ce:bold> and <ce:bold>12</ce:bold>, <ce:bold>13</ce:bold> on proliferation of human breast and pancreatic cancer cell lines.</ce:simple-para>
               </ce:caption>
               <ce:link locator="fx2"/></ce:link>
               <tgroup cols="7">
                  <colspec colnum="1" colname="col1"/></colspec>
                  <colspec colnum="2" colname="col2"/></colspec>
                  <colspec colnum="3" colname="col3"/></colspec>
                  <colspec colnum="4" colname="col4"/></colspec>
                  <colspec colnum="5" colname="col5"/></colspec>
                  <colspec colnum="6" colname="col6"/></colspec>
                  <colspec colnum="7" colname="col7"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="2">Compound</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="2">A</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="2">B</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" namest="col4" nameend="col7">IC<inf loc="post">50</inf> (μM)<cross-ref refid="tbl1fna">
                              <sup loc="post">a</sup>
                           </cross-ref>
                        </entry>
                     </row>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Breast cancer ER-Positive</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Breast cancer ER-Negative</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" namest="col6" nameend="col7">Pancreatic cancer</entry>
                     </row>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">MCF-7</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">MDA-MB-231</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">AsPC1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Panc-1</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>4</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">A2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">B1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">>10<cross-ref refid="tbl1fnb">
                              <sup loc="post">b</sup>
                           </cross-ref>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">>10</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">ND<cross-ref refid="tbl1fnc">
                              <sup loc="post">c</sup>
                           </cross-ref>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">ND</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>5</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">A1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">B1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.29</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.25</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.26</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>8</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">A1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">B2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.24</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">86.0</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">>10</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">>10</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>9</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">A4</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">B2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.9</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">8.88</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">7.54</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">8.44</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>10</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">A3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">B1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">3.31</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.53</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.54</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.64</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>12</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">A4</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">B1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.91</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.64</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.92</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.34</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>13</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">A4</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">B3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">>10</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">>10</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">>10</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">>10</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" namest="col1" nameend="col3">Niclosamide</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.06</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.79</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.47</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.73</entry>
                     </row>
                  </tbody>
               </tgroup>
               <ce:table-footnote id="tbl1fna">
                  <ce:label>a</ce:label>
                  <ce:note-para>Breast cancer cell lines: MCF-7 and MDA-MB-231. Pancreatic cancer cell lines: ASPC1 and Panc-1. Software: MasterPlex ReaderFit 2010, MiraiBio, Inc.</ce:note-para>
               </ce:table-footnote>
               <ce:table-footnote id="tbl1fnb">
                  <ce:label>b</ce:label>
                  <ce:note-para>If a specific compound is given a value >10, indicates that a specific IC<ce:inf loc="post">50</ce:inf> cannot be calculated from the data points collected, meaning ‘no effect’.</ce:note-para>
               </ce:table-footnote>
               <ce:table-footnote id="tbl1fnc">
                  <ce:label>c</ce:label>
                  <ce:note-para>ND: not determined.</ce:note-para>
               </ce:table-footnote>
            </ce:table>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" id="tbl2" frame="topbot" colsep="0" rowsep="0">
               <ce:label>Table 2</ce:label>
               <ce:caption>
                  <ce:simple-para id="tspara0015" view="all">Effects of newly synthesized compounds <ce:bold>19</ce:bold>–<ce:bold>23</ce:bold> on proliferation of human breast and pancreatic cancer cell lines.</ce:simple-para>
               </ce:caption>
               <ce:link locator="fx3"/></ce:link>
               <tgroup cols="6">
                  <colspec colnum="1" colname="col1"/></colspec>
                  <colspec colnum="2" colname="col2"/></colspec>
                  <colspec colnum="3" colname="col3"/></colspec>
                  <colspec colnum="4" colname="col4"/></colspec>
                  <colspec colnum="5" colname="col5"/></colspec>
                  <colspec colnum="6" colname="col6"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="2">Compound</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="2" align="center">R<sup loc="post">1</sup>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" namest="col3" nameend="col6">IC<inf loc="post">50</inf> (μM)<cross-ref refid="tbl2fna">
                              <sup loc="post">a</sup>
                           </cross-ref>
                        </entry>
                     </row>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Breast cancer ER-Positive</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Breast cancer ER-Negative</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" namest="col5" nameend="col6">Pancreatic cancer</entry>
                     </row>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">MCF-7</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">MDA-MB-231</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">AsPC1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Panc-1</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>5</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <inline-figure baseline="0.0">
                              <link locator="fx4"/></link>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.29</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.25</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.26</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>19</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <inline-figure baseline="0.0">
                              <link locator="fx5"/></link>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.65</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.45</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.12</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">0.31</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>20</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <inline-figure baseline="0.0">
                              <link locator="fx6"/></link>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">>10<cross-ref refid="tbl2fnb">
                              <sup loc="post">b</sup>
                           </cross-ref>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">>10</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">>10</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">>10</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>21</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <inline-figure baseline="0.0">
                              <link locator="fx7"/></link>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">>10</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">>10</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">ND<cross-ref refid="tbl2fnc">
                              <sup loc="post">c</sup>
                           </cross-ref>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">ND</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>22</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <inline-figure baseline="0.0">
                              <link locator="fx8"/></link>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">3.78</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.85</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">1.3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">3.35</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <bold>23</bold>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">
                           <inline-figure baseline="0.0">
                              <link locator="fx9"/></link>
                           </inline-figure>
                        </entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">2.97</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">6.21</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">6.97</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">7.92</entry>
                     </row>
                  </tbody>
               </tgroup>
               <ce:table-footnote id="tbl2fna">
                  <ce:label>a</ce:label>
                  <ce:note-para>Breast cancer cell lines: MCF-7 and MDA-MB-231. Pancreatic cancer cell lines: ASPC1 and Panc-1. Software: MasterPlex ReaderFit 2010, MiraiBio, Inc.</ce:note-para>
               </ce:table-footnote>
               <ce:table-footnote id="tbl2fnb">
                  <ce:label>b</ce:label>
                  <ce:note-para>If a specific compound is given a value >10, indicates that a specific IC<ce:inf loc="post">50</ce:inf> cannot be calculated from the data points collected, meaning ‘no effect’.</ce:note-para>
               </ce:table-footnote>
               <ce:table-footnote id="tbl2fnc">
                  <ce:label>c</ce:label>
                  <ce:note-para>ND: not determined.</ce:note-para>
               </ce:table-footnote>
            </ce:table>
         </ce:floats>
         <head>
            <ce:dochead>
               <ce:textfn>Original article</ce:textfn>
            </ce:dochead>
            <ce:title>Fragment-based drug design and identification of <ce:bold>HJC0123</ce:bold>, a novel orally bioavailable STAT3 inhibitor for cancer therapy</ce:title>
            <ce:author-group>
               <ce:author id="au1" author-id="S0223523413000512-5c0d8e186715b73a7da24c25fec8f810">
                  <ce:given-name>Haijun</ce:given-name>
                  <ce:surname>Chen</ce:surname>
                  <ce:cross-ref refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref refid="fn1">
                     <ce:sup loc="post">1</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au2" author-id="S0223523413000512-178c4f614bae63a21572b84d5f2966ef">
                  <ce:given-name>Zhengduo</ce:given-name>
                  <ce:surname>Yang</ce:surname>
                  <ce:cross-ref refid="aff2">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref refid="fn1">
                     <ce:sup loc="post">1</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au3" author-id="S0223523413000512-20b24ce2af6da7262510b25ac1372372">
                  <ce:given-name>Chunyong</ce:given-name>
                  <ce:surname>Ding</ce:surname>
                  <ce:cross-ref refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au4" author-id="S0223523413000512-57fe715946b374a097068ba4d0542d4f">
                  <ce:given-name>Lili</ce:given-name>
                  <ce:surname>Chu</ce:surname>
                  <ce:cross-ref refid="aff2">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au5" author-id="S0223523413000512-129b0e6856a7c3ceb2f3f964bac5734a">
                  <ce:given-name>Yusong</ce:given-name>
                  <ce:surname>Zhang</ce:surname>
                  <ce:cross-ref refid="aff2">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au6" author-id="S0223523413000512-bdc38b6efa790ed9aae0c9c5cb92f0b3">
                  <ce:given-name>Kristin</ce:given-name>
                  <ce:surname>Terry</ce:surname>
                  <ce:cross-ref refid="aff2">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au7" author-id="S0223523413000512-b613ff2f813e9f4ce45203b8dad871b7">
                  <ce:given-name>Huiling</ce:given-name>
                  <ce:surname>Liu</ce:surname>
                  <ce:cross-ref refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au8" author-id="S0223523413000512-6fca05f7fba8fd51ad71a0cb694cd518">
                  <ce:given-name>Qiang</ce:given-name>
                  <ce:surname>Shen</ce:surname>
                  <ce:cross-ref refid="aff2">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref refid="cor2">
                     <ce:sup loc="post">∗∗</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:author id="au9" author-id="S0223523413000512-5b78c862f0e9f045e74383793868ebfd">
                  <ce:given-name>Jia</ce:given-name>
                  <ce:surname>Zhou</ce:surname>
                  <ce:cross-ref refid="aff1">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref refid="cor1">
                     <ce:sup loc="post">∗</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:affiliation id="aff1">
                  <ce:label>a</ce:label>
                  <ce:textfn>Chemical Biology Program, Department of Pharmacology and Toxicology, University of Texas Medical Branch, Galveston, TX 77555, United States</ce:textfn>
               </ce:affiliation>
               <ce:affiliation id="aff2">
                  <ce:label>b</ce:label>
                  <ce:textfn>Department of Clinical Cancer Prevention, Division of Cancer Prevention and Population Sciences, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, United States</ce:textfn>
               </ce:affiliation>
               <ce:correspondence id="cor1">
                  <ce:label>∗</ce:label>
                  <ce:text>Corresponding author. Tel.: +1 409 772 9748; fax: +1 409 772 9818.</ce:text>
               </ce:correspondence>
               <ce:correspondence id="cor2">
                  <ce:label>∗∗</ce:label>
                  <ce:text>Corresponding author. Tel.: +1 713 834 6357; fax: +1 713 834 6350.</ce:text>
               </ce:correspondence>
               <ce:footnote id="fn1">
                  <ce:label>1</ce:label>
                  <ce:note-para>These authors contribute equally to this work.</ce:note-para>
               </ce:footnote>
            </ce:author-group>
            <ce:date-received day="12" month="11" year="2012"/></ce:date-received>
            <ce:date-revised day="14" month="1" year="2013"/></ce:date-revised>
            <ce:date-accepted day="17" month="1" year="2013"/></ce:date-accepted>
            <ce:abstract xml:lang="en" class="author"><ce:abstract-sec>
                  <ce:simple-para id="abspara0010" view="all">Fragment-based drug design (FBDD) is a promising approach for the generation of lead molecules with enhanced activity and especially drug-like properties against therapeutic targets. Herein, we report the fragment-based drug design, systematic chemical synthesis and pharmacological evaluation of novel scaffolds as potent anticancer agents by utilizing six privileged fragments from known STAT3 inhibitors. Several new molecules such as compounds <ce:bold>5</ce:bold>, <ce:bold>12</ce:bold>, and <ce:bold>19</ce:bold> that may act as advanced chemical leads have been identified. The most potent compound <ce:bold>5</ce:bold> (<ce:bold>HJC0123</ce:bold>) has demonstrated to inhibit STAT3 promoter activity, downregulate phosphorylation of STAT3, increase the expression of cleaved caspase-3, inhibit cell cycle progression and promote apoptosis in breast and pancreatic cancer cells with low micromolar to nanomolar IC<ce:inf loc="post">50</ce:inf> values. Furthermore, compound <ce:bold>5</ce:bold> significantly suppressed estrogen receptor (ER)-negative breast cancer MDA-MB-231 xenograft tumor growth <ce:italic>in vivo</ce:italic> (p.o.), indicating its great potential as an efficacious and orally bioavailable drug candidate for human cancer therapy.</ce:simple-para>
               </ce:abstract-sec></ce:abstract>
            <ce:abstract class="graphical">
               <ce:abstract-sec>
                  <ce:section-title>Graphical abstract</ce:section-title>
                  <ce:simple-para id="abspara0015" view="all">
                     <ce:display>
                        <ce:figure id="undfig1">
                           <ce:link locator="fx1"/></ce:link>
                        </ce:figure>
                     </ce:display>
                  </ce:simple-para>
               </ce:abstract-sec>
               <ce:abstract-sec>
                  <ce:section-title>Highlights</ce:section-title>
                  <ce:simple-para id="abspara0020" view="all">► First FBDD approach utilizing privileged fragments to target STAT3. ► Several novel scaffolds identified that may act as advanced chemical leads. ► Compound <ce:bold>5</ce:bold> (<ce:bold>HJC0123</ce:bold>) identified as a potent STAT3 inhibitor. ► The antiproliferative activity ranging from low micromolar to nanomolar IC<ce:inf loc="post">50</ce:inf> values. ► <ce:bold>HJC0123</ce:bold> significantly suppressed breast cancer xenograft tumor growth <ce:italic>in vivo</ce:italic>.</ce:simple-para>
               </ce:abstract-sec>
            </ce:abstract>
            <ce:keywords xml:lang="en" class="keyword">
               <ce:section-title>Keywords</ce:section-title>
               <ce:keyword>
                  <ce:text>Fragment-based drug design</ce:text>
               </ce:keyword>
               <ce:keyword>
                  <ce:text>Anticancer agents</ce:text>
               </ce:keyword>
               <ce:keyword>
                  <ce:text>Drug discovery</ce:text>
               </ce:keyword>
               <ce:keyword>
                  <ce:text>STAT3</ce:text>
               </ce:keyword>
               <ce:keyword>
                  <ce:text>Breast cancer</ce:text>
               </ce:keyword>
            </ce:keywords>
            <ce:keywords xml:lang="en" class="abr">
               <ce:section-title>Abbreviations</ce:section-title>
               <ce:keyword>
                  <ce:text>FBDD</ce:text>
                  <ce:keyword>
                     <ce:text>fragment-based drug design</ce:text>
                  </ce:keyword>
               </ce:keyword>
               <ce:keyword>
                  <ce:text>STATs</ce:text>
                  <ce:keyword>
                     <ce:text>signal transducers and activators of transcription</ce:text>
                  </ce:keyword>
               </ce:keyword>
               <ce:keyword>
                  <ce:text>ER</ce:text>
                  <ce:keyword>
                     <ce:text>estrogen receptor</ce:text>
                  </ce:keyword>
               </ce:keyword>
               <ce:keyword>
                  <ce:text>HBTU</ce:text>
                  <ce:keyword>
                     <ce:text>2-(1<ce:italic>H</ce:italic>-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate</ce:text>
                  </ce:keyword>
               </ce:keyword>
               <ce:keyword>
                  <ce:text>DIPEA</ce:text>
                  <ce:keyword>
                     <ce:text>
                        <ce:italic>N</ce:italic>,<ce:italic>N</ce:italic>-diisopropyleth-ylamine</ce:text>
                  </ce:keyword>
               </ce:keyword>
               <ce:keyword>
                  <ce:text>THF</ce:text>
                  <ce:keyword>
                     <ce:text>tetrahydrofuran</ce:text>
                  </ce:keyword>
               </ce:keyword>
               <ce:keyword>
                  <ce:text>SAR</ce:text>
                  <ce:keyword>
                     <ce:text>structure–activity relationships</ce:text>
                  </ce:keyword>
               </ce:keyword>
               <ce:keyword>
                  <ce:text>RLU</ce:text>
                  <ce:keyword>
                     <ce:text>relative luciferase unit</ce:text>
                  </ce:keyword>
               </ce:keyword>
               <ce:keyword>
                  <ce:text>MTS</ce:text>
                  <ce:keyword>
                     <ce:text>3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2<ce:italic>H</ce:italic>-tetrazolium)</ce:text>
                  </ce:keyword>
               </ce:keyword>
               <ce:keyword>
                  <ce:text>IC<ce:inf loc="post">50</ce:inf>
                  </ce:text>
                  <ce:keyword>
                     <ce:text>half maximal inhibitory concentration</ce:text>
                  </ce:keyword>
               </ce:keyword>
               <ce:keyword>
                  <ce:text>PI</ce:text>
                  <ce:keyword>
                     <ce:text>propidium iodide</ce:text>
                  </ce:keyword>
               </ce:keyword>
               <ce:keyword>
                  <ce:text>HRMS</ce:text>
                  <ce:keyword>
                     <ce:text>high-resolution mass spectrometry</ce:text>
                  </ce:keyword>
               </ce:keyword>
               <ce:keyword>
                  <ce:text>HPLC</ce:text>
                  <ce:keyword>
                     <ce:text>high performance liquid chromatography</ce:text>
                  </ce:keyword>
               </ce:keyword>
               <ce:keyword>
                  <ce:text>TFA</ce:text>
                  <ce:keyword>
                     <ce:text>trifluoroacetic acid</ce:text>
                  </ce:keyword>
               </ce:keyword>
               <ce:keyword>
                  <ce:text>DMSO</ce:text>
                  <ce:keyword>
                     <ce:text>dimethyl sulfoxide</ce:text>
                  </ce:keyword>
               </ce:keyword>
               <ce:keyword>
                  <ce:text>TLC</ce:text>
                  <ce:keyword>
                     <ce:text>thin layer chromatography</ce:text>
                  </ce:keyword>
               </ce:keyword>
               <ce:keyword>
                  <ce:text>NMR</ce:text>
                  <ce:keyword>
                     <ce:text>nuclear magnetic resonance</ce:text>
                  </ce:keyword>
               </ce:keyword>
               <ce:keyword>
                  <ce:text>TMS</ce:text>
                  <ce:keyword>
                     <ce:text>tetramethylsilane</ce:text>
                  </ce:keyword>
               </ce:keyword>
               <ce:keyword>
                  <ce:text>EtOAc</ce:text>
                  <ce:keyword>
                     <ce:text>ethyl acetate</ce:text>
                  </ce:keyword>
               </ce:keyword>
               <ce:keyword>
                  <ce:text>DMF</ce:text>
                  <ce:keyword>
                     <ce:text>dimethylformamide</ce:text>
                  </ce:keyword>
               </ce:keyword>
               <ce:keyword>
                  <ce:text>PBS</ce:text>
                  <ce:keyword>
                     <ce:text>phosphate-buffered saline</ce:text>
                  </ce:keyword>
               </ce:keyword>
               <ce:keyword>
                  <ce:text>BCA</ce:text>
                  <ce:keyword>
                     <ce:text>bicinchoninic acid</ce:text>
                  </ce:keyword>
               </ce:keyword>
               <ce:keyword>
                  <ce:text>SDS-PAGE</ce:text>
                  <ce:keyword>
                     <ce:text>sodium dodecyl sulfate polyacrylamide gel electrophoresis</ce:text>
                  </ce:keyword>
               </ce:keyword>
            </ce:keywords>
         </head>
         <body view="all">
            <ce:sections>
               <ce:section id="sec1" view="all">
                  <ce:label>1</ce:label>
                  <ce:section-title>Introduction</ce:section-title>
                  <ce:para id="p0010" view="all">STAT3 (signal transducers and activators of transcription 3) is a member of a family of seven transcription factors (STATs 1, 2, 3, 4, 5a, 5b, and 6) that transmit signals from cell surface receptors to the nucleus, and are crucial for the signaling of many cytokines and growth factors that are mediators in the fundamental cellular and biological processes such as the immune response, angiogenesis, cell proliferation, differentiation, and apoptosis <ce:cross-refs refid="bib1 bib2 bib3 bib4 bib5 bib6 bib7">[1–7]</ce:cross-refs>. It contains four functional domains that contribute to its oligomerization, DNA binding, Src homology 2 (SH2) dimerization, and transactivation, respectively. Once activated by extracellular signaling proteins, STAT3 is phosphorylated at a tyrosine residue 705 (Tyr-705) and phosphorylated STAT3 forms dimers via a reciprocal phosphotyrosines (pTyr)-SH2 domain interaction. Then the dimers translocate to the nucleus where they bind to specific DNA response elements and induce transcription <ce:cross-ref refid="bib8">[8]</ce:cross-ref>. In contrast to the transient nature of STAT3 activation in normal cells, constitutive STAT3 activity has been observed and reported in many human solid and hematological tumors <ce:cross-refs refid="bib9 bib10">[9,10]</ce:cross-refs>. Aberrant STAT3 activation is found to be correlated with worse prognosis by promoting tumorigenesis, inducing tumor invasion and metastasis, and driving the malignant progression in many carcinomas. Thus, STAT3 is considered to be a promising target for prevention and treatment of cancer, thereby providing the rationale to develop novel anticancer agents targeting the STAT3 signaling pathway <ce:cross-refs refid="bib11 bib12 bib13 bib14 bib15 bib16 bib17 bib18">[11–18]</ce:cross-refs>.</ce:para>
                  <ce:para id="p0015" view="all">Over the past decade, several peptidic and non-peptidic STAT3 inhibitors that directly inhibit the different structural domains of STAT3 protein or indirectly inhibit the upstream components of the STAT3 activation <ce:cross-ref refid="bib19">[19]</ce:cross-ref> such as PY*LKTK <ce:cross-ref refid="bib20">[20]</ce:cross-ref>, STX-0119 <ce:cross-ref refid="bib21">[21]</ce:cross-ref>, and S31-201 <ce:cross-ref refid="bib22">[22]</ce:cross-ref> to inhibit STAT3 dimerization, Stattic <ce:cross-ref refid="bib23">[23]</ce:cross-ref> to inhibit phosphorylation, CAP-1 <ce:cross-ref refid="bib24">[24]</ce:cross-ref> and IS3 295 <ce:cross-ref refid="bib25">[25]</ce:cross-ref> to inhibit DNA-binding, niclosamide <ce:cross-ref refid="bib26">[26]</ce:cross-ref> to inhibit transcriptional function of STAT3, WP1066 <ce:cross-ref refid="bib27">[27]</ce:cross-ref> and AG490 <ce:cross-ref refid="bib28">[28]</ce:cross-ref> to inhibit the upstream Janus kinases activity have been explored (<ce:cross-ref refid="fig1">Fig. 1</ce:cross-ref>
                     <ce:float-anchor refid="fig1"/></ce:float-anchor>). Despite these significant advances, no STAT3 inhibitor drugs have reached the market. The challenges include the lack of membrane permeability and stability, low water-solubility, weak binding affinity, or low specificity of effects <ce:cross-refs refid="bib29 bib30 bib31 bib32 bib33 bib34 bib35 bib36 bib37 bib38">[29–38]</ce:cross-refs>. Therefore, it remains highly valuable to identify novel potent and efficacious STAT3 inhibitors with new scaffolds.</ce:para>
                  <ce:para id="p0020" view="all">Fragment-based drug design (FBDD) is a promising approach for the generation of lead molecules against therapeutic targets in the past decade. New molecules with enhanced drug-likeness could be identified by chemically merging privileged-fragments from small molecule libraries that bind cooperatively in a given binding pocket <ce:cross-refs refid="bib39 bib40 bib41 bib42">[39–42]</ce:cross-refs>. These favorable fragments may maintain their original orientation in the protein binding pocket, and thus contribute jointly to the final binding energy. Till now, FBDD has proven to be a successful approach to identify potent inhibitors for specific targets <ce:cross-refs refid="bib43 bib43a bib43b bib44">[43,44]</ce:cross-refs>. Herein, we describe our efforts for the fragment-based design, synthesis and characterization of new molecules as STAT3 inhibitors for cancer therapy. Compound <ce:bold>5</ce:bold> (<ce:bold>HJC0123</ce:bold>) was discovered as a potent and orally bioavailable anticancer agent in this endeavor.</ce:para>
               </ce:section>
               <ce:section id="sec2" view="all">
                  <ce:label>2</ce:label>
                  <ce:section-title>Results and discussion</ce:section-title>
                  <ce:section id="sec2.1" view="all">
                     <ce:label>2.1</ce:label>
                     <ce:section-title>Design</ce:section-title>
                     <ce:para id="p0025" view="all">We initiated our studies with a small privileged fragment library containing six fragments selected from representative non-peptidic STAT3 inhibitors including stattic, WP1066, STX-0119, and niclosamide as potential binding pharmacophores to STAT3 (<ce:cross-ref refid="fig2">Fig. 2</ce:cross-ref>
                        <ce:float-anchor refid="fig2"/></ce:float-anchor>). The selection of the privileged fragment library was governed by data from literature with respect to the most active inhibitors of STAT3 and the drug-like properties such as molecular weight of these fragments, which ranges from 120 to 251 Da. Taking inspiration from the FBDD approach, we designed a number of novel molecules with diversified scaffolds for structure–activity relationship (SAR) studies in an attempt to identify new anticancer compounds with enhanced potency and drug-like properties.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.2" view="all">
                     <ce:label>2.2</ce:label>
                     <ce:section-title>Chemistry</ce:section-title>
                     <ce:para id="p0030" view="all">As shown in <ce:cross-refs refid="sch1 sch2">Schemes 1 and 2</ce:cross-refs>
                        <ce:float-anchor refid="sch1"/></ce:float-anchor>
                        <ce:float-anchor refid="sch2"/></ce:float-anchor>, coupling of 1,1-dioxo-1<ce:italic>H</ce:italic>-1λ<ce:sup loc="post">6</ce:sup>-benzo[<ce:italic>b</ce:italic>]thiophen-6-ylamine (<ce:bold>3</ce:bold>) with cyanoacetic acid (<ce:bold>1</ce:bold>) or 2-phenyl-quinoline-4-carboxylic acid (<ce:bold>2</ce:bold>) in the presence of HBTU and DIPEA in CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf> generated the corresponding amides <ce:bold>4</ce:bold> and <ce:bold>5</ce:bold> in moderate to high yields. Condensation of <ce:small-caps>l</ce:small-caps>(−)-α-methylbenzylamine (<ce:bold>7</ce:bold>) with 2-phenylquinoline-4-carboxylic acid (<ce:bold>2</ce:bold>) or 5-chloro-2-hydroxybenzoic acid (<ce:bold>6</ce:bold>) in the same fashion provided new compounds <ce:bold>8</ce:bold> and <ce:bold>9</ce:bold>, respectively. The synthesis of compound <ce:bold>10</ce:bold> was achieved in moderate yield via Knoevenagel condensation of 6-bromopyridine-2-carbaldehyde with the intermediate <ce:bold>4</ce:bold> in the presence of piperidine as the catalyst. The above mentioned coupling methods failed to give the desired compounds <ce:bold>12</ce:bold> and <ce:bold>13</ce:bold>, which were successfully obtained by an alternative protocol in three steps. First, the carboxylic acid <ce:bold>6</ce:bold> was converted to the acid chloride by the treatment with SOCl<ce:inf loc="post">2</ce:inf> in toluene at 120 °C for 16 h. After concentration, the acid chloride, which contained some ester formed from the hydroxyl group of phenol, was used directly for next step without further purification because the hydrolysis of the ester appendage afterward could lead to the same desired product. 1,1-Dioxo-1<ce:italic>H</ce:italic>-1λ<ce:sup loc="post">6</ce:sup>-benzo[<ce:italic>b</ce:italic>]thiophen-6-ylamine or 5-furan-2-yl-[1,3,4]oxadiazol-2-ylamine was then treated with the above acid chloride in the presence of pyridine as the base. The crude products were subsequently saponified using 1 N LiOH (aq.) in THF to generate the desired compounds <ce:bold>12</ce:bold> and <ce:bold>13</ce:bold> in yield of 39% and 50% (three steps), respectively.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.3" view="all">
                     <ce:label>2.3</ce:label>
                     <ce:section-title>Biology</ce:section-title>
                     <ce:para id="p0035" view="all">To explore the SAR, we first evaluated the <ce:italic>in vitro</ce:italic> anticancer effects of the compounds <ce:bold>4</ce:bold>, <ce:bold>5</ce:bold>, <ce:bold>8</ce:bold>–<ce:bold>10</ce:bold> and <ce:bold>12</ce:bold>, <ce:bold>13</ce:bold> on the proliferation of human breast cancer cell lines MCF-7 (ER-positive) and MDA-MB-231 (ER-negative and triple-negative), as well as pancreatic cancer cell lines AsPC1 and Panc-1 using MTS assays as described in the <ce:cross-ref refid="sec4">Experimental</ce:cross-ref> section. The ability of these new scaffolds to inhibit the growth of cancer cells is summarized in <ce:cross-ref refid="tbl1">Table 1</ce:cross-ref>
                        <ce:float-anchor refid="tbl1"/></ce:float-anchor>. It is noteworthy that most of the newly synthesized compounds described herein exhibited promising antiproliferative activity with low micromolar to nanomolar IC<ce:inf loc="post">50</ce:inf> values. Among them, compounds <ce:bold>5</ce:bold>, <ce:bold>10</ce:bold>, and <ce:bold>12</ce:bold> possessing the 1,1-dioxo-1<ce:italic>H</ce:italic>-1λ<ce:sup loc="post">6</ce:sup>-benzo[<ce:italic>b</ce:italic>]thiophen-6-yl fragment (B1) exhibited a similar or significantly higher potency than the reference compound niclosamide. Interestingly, compound <ce:bold>4</ce:bold> containing the fragment B1 and the moiety A2 instead of the 6-bromopyridin-2-yl fragment (A3) was found inactive with a dramatic loss of antiproliferative activity in comparison with compound <ce:bold>10</ce:bold>. Compounds <ce:bold>8</ce:bold> and <ce:bold>9</ce:bold> with (<ce:italic>S</ce:italic>)-(1-phenylethyl) amide moiety (B2) showed moderate to potent antiproliferative effects against the tested cancer cells. For example, compound <ce:bold>9</ce:bold> displayed an IC<ce:inf loc="post">50</ce:inf> value of 0.9 μM against ER-positive breast cancer cell line MCF-7. The salicylic amide compound <ce:bold>13</ce:bold> with the 5-furan-2-yl-[1,3,4]oxadiazol-2-yl moiety (B3) was found inactive, while compound <ce:bold>12</ce:bold> with the fragment B1 instead exhibited significant antiproliferative activity, indicating that fragment B1 rather than B3 is more favorable for the anticancer activity of molecules with the salicylic amide scaffold.</ce:para>
                     <ce:para id="p0040" view="all">Among the active new scaffolds discussed above, compound <ce:bold>5</ce:bold> notably exhibited remarkable potency against all the tested cancer cells. Since STX-0119 with the 2-phenylquinoline-4-carboxylic acid amide fragment (A1) <ce:cross-refs refid="bib21 bib45">[21,45]</ce:cross-refs> and stattic with the 1,1-dioxo-1<ce:italic>H</ce:italic>-1λ<ce:sup loc="post">6</ce:sup>-benzo[<ce:italic>b</ce:italic>]thiophen-6-yl fragment (B1) <ce:cross-ref refid="bib23">[23]</ce:cross-ref> have been reported as the STAT3-SH2 domain inhibitors, the molecular docking studies of compound <ce:bold>5</ce:bold> with both A1 and B1 fragments were performed to investigate the possible conformations and the required spatial relationship between the scaffold and STAT3-SH2 domain Ref. <ce:cross-ref refid="bib46">[46]</ce:cross-ref> using AutoDock Vina <ce:cross-ref refid="bib47">[47]</ce:cross-ref> docking approach. Examination of the predicted binding model for <ce:bold>5</ce:bold> complexed with STAT3 revealed that the 2-phenyl group on the quinoline ring could fit effectively into the hydrophobic cleft around Ile634 (<ce:cross-ref refid="fig3">Fig. 3</ce:cross-ref>
                        <ce:float-anchor refid="fig3"/></ce:float-anchor>). To further verify our findings, chemical optimization of <ce:bold>5</ce:bold> was carried out to gain insights on this potential series. Additional five compounds (<ce:bold>19</ce:bold>–<ce:bold>23</ce:bold>) with different hydrophobic groups were prepared (<ce:cross-ref refid="sch3">Scheme 3</ce:cross-ref>
                        <ce:float-anchor refid="sch3"/></ce:float-anchor>), analogously to the synthesis of <ce:bold>4</ce:bold> and <ce:bold>5</ce:bold> described above, and their anticancer activities were evaluated in the same fashion (<ce:cross-ref refid="tbl2">Table 2</ce:cross-ref>
                        <ce:float-anchor refid="tbl2"/></ce:float-anchor>).</ce:para>
                     <ce:para id="p0045" view="all">The obtained SAR results suggest that the hydrophobic substituent at C2 of the quinoline or pyridine framework is crucial for targeting STAT3. For example, compounds <ce:bold>20</ce:bold>, <ce:bold>21</ce:bold> and <ce:bold>23</ce:bold> without the 2-Ph moiety displayed moderate to low antiproliferative activity against the tested cancer cells. Instead, compound <ce:bold>22</ce:bold> with 2-Ph group in contrast with compound <ce:bold>21</ce:bold> regained antiproliferative activity with low micromolar IC<ce:inf loc="post">50</ce:inf> values. Compound <ce:bold>19</ce:bold> with an additional phenyl substituent at the 6-position of pyridine ring exhibited further enhanced anticancer activity when compared with compound <ce:bold>22</ce:bold>, indicating the important role of hydrophobic substituents on the quinoline and pyridine fragments.</ce:para>
                     <ce:para id="p0050" view="all">Through the SAR studies, compound <ce:bold>5</ce:bold> has been identified with most desirable antiproliferative activity and physicochemical parameters (see <ce:cross-ref refid="appsec1">Table S1</ce:cross-ref> in the Supporting information), and was subjected to further biological characterization. Cellular morphological change in MDA-MB-231 breast cancer cells treating with compound <ce:bold>5</ce:bold> for 48 h was examined under light microscopy. As shown in <ce:cross-ref refid="appsec1">Fig. S1</ce:cross-ref>, compound <ce:bold>5</ce:bold> significantly inhibited cell proliferation and induced apoptosis accompanying cellular morphological changes in a dose-dependent manner.</ce:para>
                     <ce:para id="p0055" view="all">To determine whether compound <ce:bold>5</ce:bold> acts as a potent small-molecule inhibitor of STAT3 activation, we measured the effect of <ce:bold>5</ce:bold> on promoter activity using the cell-based transient transfection and dual luciferase reporter assays. The STAT3 promoter activity in MDA-MB-231 cells was determined after transient transfecting with pSTAT3-Luc vector. As shown in <ce:cross-ref refid="fig4">Fig. 4</ce:cross-ref>
                        <ce:float-anchor refid="fig4"/></ce:float-anchor>, treatment with 5 μM of compound <ce:bold>5</ce:bold> inhibited the STAT3 promoter activity in MDA-MB-231 cells by approximately 65% compared with control.</ce:para>
                     <ce:para id="p0060" view="all">To further investigate the inhibitory activity of compound <ce:bold>5</ce:bold> against the STAT3 pathway, we examined STAT3 phosphorylation and expression of the known STAT3 target genes in MDA-MB-231 cell line. The cells were treated with different doses of compound <ce:bold>5</ce:bold> for 24 h and 48 h, and levels of total STAT3 and phosphorylated STAT3 at Tyr-705 were then examined by Western blot. It was found that the total STAT3 expression in these cells was reduced after the treatment with compound <ce:bold>5</ce:bold> (<ce:cross-ref refid="fig5">Fig. 5</ce:cross-ref>
                        <ce:float-anchor refid="fig5"/></ce:float-anchor>). Similarly, phosphorylated STAT3 at Tyr-705 was suppressed by compound <ce:bold>5</ce:bold>. Blocking STAT3 signaling in many different tumor cells leads to growth arrest and apoptosis <ce:cross-refs refid="bib7 bib22 bib48 bib49 bib50">[7,22,48–50]</ce:cross-refs>. To investigate whether compound <ce:bold>5</ce:bold> induces apoptosis, we first determined its ability in inducing cleaved caspase 3 in MDA-MB-231 breast cancer cells. As shown in <ce:cross-ref refid="fig5">Fig. 5</ce:cross-ref>, compound <ce:bold>5</ce:bold> induced a higher cleaved caspase-3 level in MDA-MB-231 cells, suggesting that compound <ce:bold>5</ce:bold> promoted the apoptosis of cancer cells. We further confirmed these results using annexin V-based measurement using flow cytometry. As depicted in <ce:cross-ref refid="appsec1">Fig. S2</ce:cross-ref>, compound <ce:bold>5</ce:bold> activated apoptosis in MDA-MB-231 breast cancer cells in a dose-dependent manner. Further flow cytometry analysis revealed that compound <ce:bold>5</ce:bold> arrested MDA-MB-231 cells at S phase in a dose-dependent manner (<ce:cross-ref refid="appsec1">Fig. S3</ce:cross-ref>). These results suggested that compound <ce:bold>5</ce:bold> was conferred the ability to arrest cells. The more extensive mechanism studies on compound <ce:bold>5</ce:bold> including STAT3 upstream targets and related signaling pathways are undergoing, and the results will be reported somewhere else in due course.</ce:para>
                     <ce:para id="p0065" view="all">Compound <ce:bold>5</ce:bold> was next evaluated for its antitumor activity in inhibition of tumor growth in the MDA-MB-231 xenograft model. MDA-MB-231 xenograft tumors were developed in immunodeficient nude mice and tumor volume was measured daily in oral gavage (p.o.) group. We treated the MDA-MB-231 xenograft mice through oral administration of compound <ce:bold>5</ce:bold> (50 mg/kg) and found that the growth of xenograft tumors in mice was significantly suppressed by compound <ce:bold>5</ce:bold> (<ce:cross-ref refid="fig6">Fig. 6</ce:cross-ref>
                        <ce:float-anchor refid="fig6"/></ce:float-anchor>). Notably, compound <ce:bold>5</ce:bold> did not show significant signs of toxicity even at the dose of 150 mg/kg (data not shown). These results have demonstrated that compound <ce:bold>5</ce:bold> is a potent, efficacious and orally bioavailable anti-cancer drug candidate that is promising for further clinical development.</ce:para>
                  </ce:section>
               </ce:section>
               <ce:section id="sec3" view="all">
                  <ce:label>3</ce:label>
                  <ce:section-title>Conclusions</ce:section-title>
                  <ce:para id="p0070" view="all">Taken together, a fragment-based drug design, systematic chemical synthesis and pharmacological evaluation of novel scaffolds as potent anticancer agents have been carried out by utilizing six privileged fragments from known STAT3 inhibitors. Several new molecules such as compounds <ce:bold>5</ce:bold>, <ce:bold>12</ce:bold>, and <ce:bold>19</ce:bold> that may act as advanced chemical leads have been identified. The most potent compound <ce:bold>5</ce:bold> has demonstrated to inhibit STAT3 promoter activity, down-regulate phospho-STAT3, increase the expression of cleaved caspase-3, inhibit cell cycle progression and promote apoptosis in breast and pancreatic cancer cells with low micromolar to nanomolar IC<ce:inf loc="post">50</ce:inf> values. Furthermore, compound <ce:bold>5</ce:bold> significantly suppressed ER-negative breast cancer MDA-MB-231 xenograft tumor growth <ce:italic>in vivo</ce:italic> (p.o.), indicating its great potential as an efficacious and orally bioavailable drug candidate for human cancer therapy. This promising compound has been selected for further preclinical assessment and the results will be reported somewhere else in due course.</ce:para>
               </ce:section>
               <ce:section id="sec4" view="all">
                  <ce:label>4</ce:label>
                  <ce:section-title>Experimental</ce:section-title>
                  <ce:section id="sec4.1" view="all">
                     <ce:label>4.1</ce:label>
                     <ce:section-title>Chemistry</ce:section-title>
                     <ce:para id="p0075" view="all">All commercially available starting materials and solvents were reagent grade, and used without further purification. Reactions were performed under a nitrogen atmosphere in dry glassware with magnetic stirring. Preparative column chromatography was performed using silica gel 60, particle size 0.063–0.200 mm (70–230 mesh, flash). Analytical TLC was carried out employing silica gel 60 F254 plates (Merck, Darmstadt). Visualization of the developed chromatograms was performed with detection by UV (254 nm). NMR spectra were recorded on a Brucker-600 (<ce:sup loc="pre">1</ce:sup>H, 600 MHz; <ce:sup loc="pre">13</ce:sup>C, 150 MHz) spectrometer. <ce:sup loc="pre">1</ce:sup>H and <ce:sup loc="pre">13</ce:sup>C NMR spectra were recorded with TMS as an internal reference. Chemical shifts were expressed in ppm, and <ce:italic>J</ce:italic> values were given in Hz. High-resolution mass spectra (HRMS) were obtained from Thermo Fisher LTQ Orbitrap Elite mass spectrometer. Parameters include the following: Nano ESI spray voltage was 1.8 kV; capillary temperature was 275 °C and the resolution was 60,000; ionization was achieved by positive mode. Melting points were measured on a Thermo Scientific Electrothermal Digital Melting Point Apparatus and uncorrected. Purity of final compounds was determined by analytical HPLC, which was carried out on a Shimadzu HPLC system (model: CBM-20A LC-20AD SPD-20A UV/VIS). HPLC analysis conditions: Waters μBondapak C18 (300 × 3.9 mm); flow rate 0.5 mL/min; UV detection at 270 and 254 nm; linear gradient from 30% acetonitrile in water (0.1% TFA) to 100% acetonitrile (0.1% TFA) in 20 min followed by 30 min of the last-named solvent. All biologically evaluated compounds are >95% pure.</ce:para>
                     <ce:section id="sec4.1.1" view="all">
                        <ce:label>4.1.1</ce:label>
                        <ce:section-title>2-Cyano-<ce:italic>N</ce:italic>-(1,1-dioxo-1<ce:italic>H</ce:italic>-1λ<ce:sup loc="post">6</ce:sup>-benzo[<ce:italic>b</ce:italic>]thiophen-6-yl)acetamide (<ce:bold>4</ce:bold>)</ce:section-title>
                        <ce:para id="p0080" view="all">To a solution of cyanoacetic acid (340 mg, 4.0 mmol) and 1,1-dioxo-1<ce:italic>H</ce:italic>-1λ<ce:sup loc="post">6</ce:sup>-benzo[<ce:italic>b</ce:italic>]thiophen-6-ylamine (362 mg, 2.0 mmol) in 10 mL of CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf> was added DIPEA (774 mg, 6.0 mmol). HBTU (1.14 g, 3.0 mmol) was added at 0 °C. The resulting mixture was stirred at r.t. for 28 h. The reaction mixture was diluted with CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf> (80 mL) and washed with water (20 mL). The organic layer was separated and dried with anhydrous Na<ce:inf loc="post">2</ce:inf>SO<ce:inf loc="post">4</ce:inf>. The solution was concentrated to give a crude product, which was purified with silica gel column (EtOAc/hexane = 1/1) to obtain the desired product (400 mg, 81%) as a yellow solid (mp 207–208 °C). HPLC purity 98.6% (<ce:italic>t</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>R</ce:italic>
                           </ce:inf> = 10.93 min). <ce:sup loc="pre">1</ce:sup>H NMR (600 MHz, DMSO-<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 10.79 (s, 1H), 8.04 (s, 1H), 7.67–7.69 (m, 1H), 7.60 (d, 1H, <ce:italic>J</ce:italic> = 7.2 Hz), 7.57 (d, 1H, <ce:italic>J</ce:italic> = 7.8 Hz), 7.30 (d, 1H, <ce:italic>J</ce:italic> = 7.2 Hz), 3.98 (s, 2H). <ce:sup loc="pre">13</ce:sup>C NMR (150 MHz, DMSO-<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 162.0, 140.7, 137.3, 132.8, 130.3, 126.7, 126.1, 123.4, 115.6, 111.4, 27.0. HRMS (ESI) calcd for C<ce:inf loc="post">11</ce:inf>H<ce:inf loc="post">19</ce:inf>N<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">3</ce:inf>S 249.0328 (M + H)<ce:sup loc="post">+</ce:sup>, found 249.0330.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.2" view="all">
                        <ce:label>4.1.2</ce:label>
                        <ce:section-title>2-Phenylquinoline-4-carboxylic acid (1,1-dioxo-1<ce:italic>H</ce:italic>-1λ<ce:sup loc="post">6</ce:sup>-benzo[<ce:italic>b</ce:italic>]thiophen-6-yl)amide (<ce:bold>5</ce:bold>)</ce:section-title>
                        <ce:para id="p0085" view="all">To a solution of 2-phenylquinoline-4-carboxylic acid (249 mg, 1.0 mmol) and 1,1-dioxo-1<ce:italic>H</ce:italic>-1λ<ce:sup loc="post">6</ce:sup>-benzo[<ce:italic>b</ce:italic>]thiophen-6-ylamine (181 mg, 1.0 mmol) in 10 mL of CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf> was added DIPEA (387 mg, 3.0 mmol). HBTU (759 mg, 2.0 mmol) was added at 0 °C. The resulting mixture was stirred at r.t. for 48 h. The reaction mixture was diluted with EtOAc (300 mL) and washed with water (50 mL). The organic layer was separated and dried with anhydrous Na<ce:inf loc="post">2</ce:inf>SO<ce:inf loc="post">4</ce:inf>. The solution was concentrated to give a crude product, which was further purified with short silica gel column (EtOAc/hexane = 1/1 to 4/1) to obtain the desired product (160 mg, 39%) as a pale yellow solid (mp 277–278 °C). HPLC purity 99.2% (<ce:italic>t</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>R</ce:italic>
                           </ce:inf> = 32.39 min). <ce:sup loc="pre">1</ce:sup>H NMR (600 MHz, DMSO-<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 11.29 (s, 1H), 8.44 (s, 1H), 8.38 (d, 2H, <ce:italic>J</ce:italic> = 7.2 Hz), 8.34 (s, 1H), 8.20 (dd, 2H, <ce:italic>J</ce:italic> = 5.4 Hz, 13.8 Hz), 7.98 (d, 1H, <ce:italic>J</ce:italic> = 7.8 Hz), 7.88 (t, 1H, <ce:italic>J</ce:italic> = 7.2 Hz), 7.54–7.70 (m, 6H), 7.34 (d, 1H, <ce:italic>J</ce:italic> = 6.6 Hz). <ce:sup loc="pre">13</ce:sup>C NMR (150 MHz, DMSO-<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 165.8, 155.8, 147.9, 142.2, 141.2, 138.0, 137.2, 132.9, 130.5, 130.4, 130.0, 129.7, 129.0, 127.6, 127.3, 126.6, 126.3, 125.1, 124.2, 123.0, 117.1, 117.1, 112.3, 112.3. HRMS (ESI) calcd for C<ce:inf loc="post">24</ce:inf>H<ce:inf loc="post">17</ce:inf>N<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">3</ce:inf>S 413.0954 (M + H)<ce:sup loc="post">+</ce:sup>, found 413.0959.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.3" view="all">
                        <ce:label>4.1.3</ce:label>
                        <ce:section-title>(<ce:italic>S</ce:italic>)-2-Phenylquinoline-4-carboxylic acid (1-phenylethyl)amide (<ce:bold>8</ce:bold>)</ce:section-title>
                        <ce:para id="p0090" view="all">To a solution of 2-phenyl-quinoline-4-carboxylic acid (249 mg, 1.0 mmol) and <ce:small-caps>l</ce:small-caps>(−)-α-methylbenzylamine (127 mg, 1.05 mmol) in 10 mL of CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf> was added DIPEA (388 mg, 3.0 mmol). HBTU (569 mg, 1.5 mmol) was added at 0 °C. The resulting mixture was stirred at r.t. for 3 h. The reaction mixture was diluted with CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf> (80 mL) and washed with water (20 mL). The organic layer was separated and dried with anhydrous Na<ce:inf loc="post">2</ce:inf>SO<ce:inf loc="post">4</ce:inf>. The solution was concentrated to give a crude product, which was purified with silica gel column (EtOAc/hexane = 1/3) to obtain <ce:bold>8</ce:bold> (330 mg, 94%) as a white solid (mp 157–158 °C). HPLC purity 99.8% (<ce:italic>t</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>R</ce:italic>
                           </ce:inf> = 17.22 min). <ce:sup loc="pre">1</ce:sup>H NMR (600 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 8.03–8.07 (m, 3H), 7.97 (d, 1H, <ce:italic>J</ce:italic> = 8.4 Hz), 7.71 (s, 1H), 7.67 (t, 1H, <ce:italic>J</ce:italic> = 7.2 Hz), 7.28–7.48 (m, 9H), 6.78 (d, 1H, <ce:italic>J</ce:italic> = 7.2 Hz), 5.38–5.43 (m, 1H), 1.66 (d, 3H, <ce:italic>J</ce:italic> = 6.6 Hz). <ce:sup loc="pre">13</ce:sup>C NMR (150 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 166.9, 156.9, 148.7, 143.0, 142.6, 138.9, 130.3, 130.2, 129.8, 129.0, 127.8, 127.6, 127.4, 126.4, 125.0, 123.4, 116.4, 49.8, 21.9. HRMS (ESI) calcd for C<ce:inf loc="post">24</ce:inf>H<ce:inf loc="post">21</ce:inf>N<ce:inf loc="post">2</ce:inf>O 353.1648 (M + H)<ce:sup loc="post">+</ce:sup>, found 353.1653.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.4" view="all">
                        <ce:label>4.1.4</ce:label>
                        <ce:section-title>(<ce:italic>S</ce:italic>)-5-Chloro-2-hydroxy-<ce:italic>N</ce:italic>-(1-phenylethyl)benzamide (<ce:bold>9</ce:bold>)</ce:section-title>
                        <ce:para id="p0095" view="all">Compound <ce:bold>9</ce:bold> was prepared in 39% yield by a procedure similar to that used to prepare compound <ce:bold>8</ce:bold>. The title compound was obtained as a white solid (mp 124–125 °C). HPLC purity 97.1% (<ce:italic>t</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>R</ce:italic>
                           </ce:inf> = 19.75 min). <ce:sup loc="pre">1</ce:sup>H NMR (600 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 12.22 (s, 1H), 7.28–7.48 (m, 7H), 6.93 (d, 1H, <ce:italic>J</ce:italic> = 9.0 Hz), 6.55 (d, 1H, <ce:italic>J</ce:italic> = 6.6 Hz), 5.29–5.34 (m, 1H), 1.64 (d, 3H, <ce:italic>J</ce:italic> = 7.2 Hz). <ce:sup loc="pre">13</ce:sup>C NMR (150 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 168.2, 160.4, 142.3, 134.3, 129.1, 128.0, 126.3, 125.1, 123.4, 120.3, 115.3, 49.5, 21.7. HRMS (ESI) calcd for C<ce:inf loc="post">15</ce:inf>H<ce:inf loc="post">15</ce:inf>ClNO<ce:inf loc="post">2</ce:inf> 276.0786 (M + H)<ce:sup loc="post">+</ce:sup>, found 276.0790.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.5" view="all">
                        <ce:label>4.1.5</ce:label>
                        <ce:section-title>3-(6-Bromopyridin-2-yl)-2-cyano-<ce:italic>N</ce:italic>-(1,1-dioxo-1<ce:italic>H</ce:italic>-1λ<ce:sup loc="post">6</ce:sup>-benzo[<ce:italic>b</ce:italic>]thiophen-6-yl)acrylamide (<ce:bold>10</ce:bold>)</ce:section-title>
                        <ce:para id="p0100" view="all">To a solution of <ce:bold>4</ce:bold> (100 mg, 0.40 mmol) and 6-bromo-pyridine-2-carbaldehyde (112 mg, 0.60 mmol) in EtOH (5 mL) was added piperidine (3 mg, 0.04 mmol) at 0 °C. The mixture was stirred at 90 °C for 0.5 h. A yellow suspension formed during the reaction. The solid was filtered and washed with H<ce:inf loc="post">2</ce:inf>O. The desired product (120 mg, 72%) was obtained as a yellow solid (mp 219–220 °C). HPLC purity 96.0% (<ce:italic>t</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>R</ce:italic>
                           </ce:inf> = 16.57 min). <ce:sup loc="pre">1</ce:sup>H NMR (600 MHz, DMSO-<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 10.94 (s, 1H), 8.24 (s, 1H), 8.14 (s, 1H), 7.98 (t, 1H, <ce:italic>J</ce:italic> = 7.8 Hz), 7.91–7.93 (m, 2H), 7.84 (d, 1H, <ce:italic>J</ce:italic> = 7.8 Hz), 7.62 (t, 2H, <ce:italic>J</ce:italic> = 7.2 Hz), 7.34 (d, 1H, <ce:italic>J</ce:italic> = 7.2 Hz). <ce:sup loc="pre">13</ce:sup>C NMR (150 MHz, DMSO-<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 160.7, 150.8, 147.2, 141.3, 140.8, 140.6, 137.1, 132.7, 130.9, 130.5, 126.7, 126.6, 126.6, 124.8, 114.6, 112.8, 110.8. HRMS (ESI) calcd for C<ce:inf loc="post">17</ce:inf>H<ce:inf loc="post">11</ce:inf>BrN<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">3</ce:inf>S 415.9699 (M + H)<ce:sup loc="post">+</ce:sup>, found 415.9703.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.6" view="all">
                        <ce:label>4.1.6</ce:label>
                        <ce:section-title>5-Chloro-<ce:italic>N</ce:italic>-(1,1-dioxo-1<ce:italic>H</ce:italic>-1λ<ce:sup loc="post">6</ce:sup>-benzo[<ce:italic>b</ce:italic>]thiophen-6-yl)-2-hydroxybenzamide (<ce:bold>12</ce:bold>)</ce:section-title>
                        <ce:para id="p0105" view="all">A solution of 5-chloro-2-hydroxybenzoic acid (2.0 g, 11 mmol) and 4 mL of SOCl<ce:inf loc="post">2</ce:inf> in 4 mL of toluene was stirred at 110 °C overnight. The mixture was concentrated to give a crude product as a pale yellow oil. To the solution of pyridine (869 mg, 11 mmol) and 1,1-dioxo-1<ce:italic>H</ce:italic>-1λ<ce:sup loc="post">6</ce:sup>-benzo[<ce:italic>b</ce:italic>]thiophen-6-ylamine (200 mg, 1.1 mmol) was added the solution of the acid chloride (500 mg, 2.6 mmol) in DMF (15 mL) dropwise at 0 °C. The mixture was stirred at r.t. for 24 h. The mixture was added to the water solution dropwise. The yellow solid was formed and filtrated. To the mixture of the crude product in THF (8 mL) was added 1 N LiOH (2.2 mL, 2.2 mmol) at 0 °C. The mixture was stirred at 0 °C for 30 min. The mixture was diluted with EtOAc (50 mL) and washed with 2 N HCl (10 mL). The organic layer was separated and dried with anhydrous Na<ce:inf loc="post">2</ce:inf>SO<ce:inf loc="post">4</ce:inf>. The solution was concentrated to afford the crude product, which was washed with CH<ce:inf loc="post">2</ce:inf>Cl<ce:inf loc="post">2</ce:inf> (20 mL) to give the desired product (150 mg, 39%) as a yellow solid (mp 268–269 °C). HPLC purity 98.3% (<ce:italic>t</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>R</ce:italic>
                           </ce:inf> = 17.24 min). <ce:sup loc="pre">1</ce:sup>H NMR (600 MHz, DMSO-<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 11.50 (s, 1H), 10.74 (s, 1H), 8.25 (s, 1H), 7.92 (d, 1H, <ce:italic>J</ce:italic> = 8.4 Hz), 7.86 (d, 1H, <ce:italic>J</ce:italic> = 2.4 Hz), 7.59–7.62 (m, 2 H), 7.48 (d, 1H, <ce:italic>J</ce:italic> = 9.0 Hz), 7.31 (d, 1H, <ce:italic>J</ce:italic> = 6.6 Hz), 7.04 (d, 1H, <ce:italic>J</ce:italic> = 8.4 Hz). <ce:sup loc="pre">13</ce:sup>C NMR (150 MHz, DMSO-<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 165.1, 156.2, 140.7, 137.1, 133.1, 132.8, 130.3, 128.6, 126.5, 126.2, 124.6, 122.8, 120.4, 119.0, 112.7. HRMS (ESI) calcd for C<ce:inf loc="post">15</ce:inf>H<ce:inf loc="post">11</ce:inf>ClNO<ce:inf loc="post">4</ce:inf>S 336.0092 (M + H)<ce:sup loc="post">+</ce:sup>, found 336.0098.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.7" view="all">
                        <ce:label>4.1.7</ce:label>
                        <ce:section-title>5-Chloro-<ce:italic>N</ce:italic>-(5-furan-2-yl-[1,3,4]oxadiazol-2-yl)-2-hydroxybenzamide (<ce:bold>13</ce:bold>)</ce:section-title>
                        <ce:para id="p0110" view="all">Compound <ce:bold>13</ce:bold> was prepared in 50% yield by a procedure similar to that used to prepare compound <ce:bold>12</ce:bold>. The title compound was obtained as a white solid (mp 196–197 °C). HPLC purity 96.0% (<ce:italic>t</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>R</ce:italic>
                           </ce:inf> = 18.99 min). <ce:sup loc="pre">1</ce:sup>H NMR (600 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 10.11 (s, 1H), 8.13 (d, 1H, <ce:italic>J</ce:italic> = 2.4 Hz), 8.02 (d, 1H, <ce:italic>J</ce:italic> = 2.4 Hz), 7.64 (dd, 1H, <ce:italic>J</ce:italic> = 2.4 Hz and 8.4 Hz), 7.49 (dd, 1H, <ce:italic>J</ce:italic> = 2.4 Hz and 8.4 Hz), 7.21 (d, 1H, <ce:italic>J</ce:italic> = 9.0 Hz), 6.99 (d, 1H, <ce:italic>J</ce:italic> = 9.0 Hz). <ce:sup loc="pre">13</ce:sup>C NMR (150 MHz, DMSO-<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 164.4, 158.4, 148.3, 135.2, 133.6, 130.8, 130.6, 130.2, 126.2, 125.9, 122.6, 119.7, 115.4. HRMS (ESI) calcd for C<ce:inf loc="post">13</ce:inf>H<ce:inf loc="post">9</ce:inf>ClN<ce:inf loc="post">3</ce:inf>O<ce:inf loc="post">4</ce:inf> 306.0276 (M + H)<ce:sup loc="post">+</ce:sup>, found 306.0274.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.8" view="all">
                        <ce:label>4.1.8</ce:label>
                        <ce:section-title>
                           <ce:italic>N</ce:italic>-(1,1-Dioxo-1<ce:italic>H</ce:italic>-1λ<ce:sup loc="post">6</ce:sup>-benzo[<ce:italic>b</ce:italic>]thiophen-6-yl)-2,6-diphenyl-isonicotinamide (<ce:bold>19</ce:bold>)</ce:section-title>
                        <ce:para id="p0115" view="all">Compound <ce:bold>19</ce:bold> was prepared in 50% yield by a procedure similar to that used to prepare compound <ce:bold>4</ce:bold>. The title compound was obtained as a pale yellow solid (mp 235–236 °C). HPLC purity 97.2% (<ce:italic>t</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>R</ce:italic>
                           </ce:inf> = 22.05 min). <ce:sup loc="pre">1</ce:sup>H NMR (600 MHz, CDCl<ce:inf loc="post">3</ce:inf>) <ce:italic>δ</ce:italic> 8.76 (s, 1H), 8.34 (d, 1H, <ce:italic>J</ce:italic> = 6.6 Hz), 8.23 (d, 4H, <ce:italic>J</ce:italic> = 7.2 Hz), 8.14 (s, 2H) 7.93 (s, 1H), 7.41–7.55 (m, 6H), 7.40 (d, 1H, <ce:italic>J</ce:italic> = 8.4 Hz), 7.13–7.15 (m, 1H), 6.26–6.28 (m, 1H). <ce:sup loc="pre">13</ce:sup>C NMR (150 MHz, DMSO-<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 164.7, 156.6, 143.9, 141.1, 138.1, 137.1, 132.8, 130.4, 129.7, 129.0, 126.9, 126.6, 126.3, 124.6, 116.7, 112.7. HRMS (ESI) calcd for C<ce:inf loc="post">26</ce:inf>H<ce:inf loc="post">19</ce:inf>N<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">3</ce:inf>S 439.1111 (M + H)<ce:sup loc="post">+</ce:sup>, found 439.1116.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.9" view="all">
                        <ce:label>4.1.9</ce:label>
                        <ce:section-title>Acridine-9-carboxylic acid (1,1-dioxo-1<ce:italic>H</ce:italic>-1λ<ce:sup loc="post">6</ce:sup>-benzo[<ce:italic>b</ce:italic>]thiophen-6-yl)amide (<ce:bold>20</ce:bold>)</ce:section-title>
                        <ce:para id="p0120" view="all">Compound <ce:bold>20</ce:bold> was prepared in 39% yield by a procedure similar to that used to prepare compound <ce:bold>4</ce:bold>. The title compound was obtained as a yellow solid (mp 237–238 °C). HPLC purity 99.4% (<ce:italic>t</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>R</ce:italic>
                           </ce:inf> = 14.48 min). <ce:sup loc="pre">1</ce:sup>H NMR (600 MHz, DMSO-<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 8.71 (d, 1H, <ce:italic>J</ce:italic> = 8.4 Hz), 8.32 (d, 2H, <ce:italic>J</ce:italic> = 8.4 Hz), 8.08–8.13 (m, 5 H), 7.97 (t, 2H, <ce:italic>J</ce:italic> = 7.8 Hz), 7.82 (t, 1H, <ce:italic>J</ce:italic> = 8.4 Hz), 7.68 (t, 2H, <ce:italic>J</ce:italic> = 7.8 Hz). <ce:sup loc="pre">13</ce:sup>C NMR (150 MHz, DMSO-<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 163.4, 147.9, 136.1, 133.9, 132.9, 131.1, 129.5, 128.0, 128.0, 125.2, 121.7, 116.5, 115.5. HRMS (ESI) calcd for C<ce:inf loc="post">22</ce:inf>H<ce:inf loc="post">15</ce:inf>N<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">3</ce:inf>S 387.0798 (M + H)<ce:sup loc="post">+</ce:sup>, found 387.0802.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.10" view="all">
                        <ce:label>4.1.10</ce:label>
                        <ce:section-title>
                           <ce:italic>N</ce:italic>-(1,1-Dioxo-1<ce:italic>H</ce:italic>-1λ<ce:sup loc="post">6</ce:sup>-benzo[<ce:italic>b</ce:italic>]thiophen-6-yl)isonicotinamide (<ce:bold>21</ce:bold>)</ce:section-title>
                        <ce:para id="p0125" view="all">Compound <ce:bold>21</ce:bold> was prepared in 56% yield by a procedure similar to that used to prepare compound <ce:bold>4</ce:bold>. The title compound was obtained as a pale yellow solid (mp 251–252 °C). HPLC purity 97.0% (<ce:italic>t</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>R</ce:italic>
                           </ce:inf> = 8.81 min). <ce:sup loc="pre">1</ce:sup>H NMR (600 MHz, DMSO-<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 10.92 (s, 1H), 8.81–8.82 (m, 2H), 8.27 (s, 1H), 8.00 (d, 1H, <ce:italic>J</ce:italic> = 7.8 Hz), 7.88 (t, 2H, <ce:italic>J</ce:italic> = 2.4 Hz), 7.62 (t, 2H, <ce:italic>J</ce:italic> = 6.6 Hz), 7.33 (d, 1H, <ce:italic>J</ce:italic> = 6.6 Hz). <ce:sup loc="pre">13</ce:sup>C NMR (150 MHz, DMSO-<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 164.6, 150.4, 141.3, 141.1, 137.1, 132.8, 130.4, 126.5, 126.3, 124.5, 121.6, 112.6. HRMS (ESI) calcd for C<ce:inf loc="post">14</ce:inf>H<ce:inf loc="post">11</ce:inf>N<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">3</ce:inf>S 287.0485 (M + H)<ce:sup loc="post">+</ce:sup>, found 287.0488.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.11" view="all">
                        <ce:label>4.1.11</ce:label>
                        <ce:section-title>
                           <ce:italic>N</ce:italic>-(1,1-Dioxo-1<ce:italic>H</ce:italic>-1λ<ce:sup loc="post">6</ce:sup>-benzo[<ce:italic>b</ce:italic>]thiophen-6-yl)-2-phenyl-isonicotinamide (<ce:bold>22</ce:bold>)</ce:section-title>
                        <ce:para id="p0130" view="all">Compound <ce:bold>22</ce:bold> was prepared in 46% yield by a procedure similar to that used to prepare compound <ce:bold>4</ce:bold>. The title compound was obtained as a pale yellow solid (mp 285–286 °C). HPLC purity 98.0% (<ce:italic>t</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>R</ce:italic>
                           </ce:inf> = 14.72 min). <ce:sup loc="pre">1</ce:sup>H NMR (600 MHz, DMSO-<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 10.97 (s, 1H), 8.89 (d, 1H, <ce:italic>J</ce:italic> = 4.8 Hz), 8.42 (s, 1H), 8.28 (s, 1H), 8.19 (d, 2H, <ce:italic>J</ce:italic> = 7.8 Hz), 8.03–8.05 (m, 1H), 7.82 (d, 1H, <ce:italic>J</ce:italic> = 4.8 Hz), 7.63 (d, 2H, <ce:italic>J</ce:italic> = 7.8 Hz), 7.56 (t, 1H, <ce:italic>J</ce:italic> = 7.2 Hz), 7.51 (t, 2H, <ce:italic>J</ce:italic> = 7.2 Hz), 7.34 (d, 1H, <ce:italic>J</ce:italic> = 6.6 Hz). <ce:sup loc="pre">13</ce:sup>C NMR (150 MHz, DMSO-<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 164.6, 156.9, 150.4, 142.6, 141.1, 138.1, 137.1, 132.8, 130.4, 129.6, 128.9, 126.8, 126.5, 126.3, 124.6, 120.5, 118.0, 112.7. HRMS (ESI) calcd for C<ce:inf loc="post">20</ce:inf>H<ce:inf loc="post">15</ce:inf>N<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">3</ce:inf>S 363.0798 (M + H)<ce:sup loc="post">+</ce:sup>, found 363.0791.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.1.12" view="all">
                        <ce:label>4.1.12</ce:label>
                        <ce:section-title>Quinoline-3-carboxylic acid (1,1-dioxo-1<ce:italic>H</ce:italic>-1λ<ce:sup loc="post">6</ce:sup>-benzo[<ce:italic>b</ce:italic>]thiophen-6-yl)amide (<ce:bold>23</ce:bold>)</ce:section-title>
                        <ce:para id="p0135" view="all">Compound <ce:bold>23</ce:bold> was prepared in 48% yield by a procedure similar to that used to prepare compound <ce:bold>4</ce:bold>. The title compound was obtained as a pale yellow solid (mp 209–210 °C). HPLC purity 98.8% (<ce:italic>t</ce:italic>
                           <ce:inf loc="post">
                              <ce:italic>R</ce:italic>
                           </ce:inf> = 11.01 min). <ce:sup loc="pre">1</ce:sup>H NMR (600 MHz, acetone-<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 10.29 (s, 1H), 9.03 (d, 1H, <ce:italic>J</ce:italic> = 4.2 Hz), 8.42 (s, 1H), 8.34 (d, 1H, <ce:italic>J</ce:italic> = 8.4 Hz), 8.14 (d, 1H, <ce:italic>J</ce:italic> = 8.4 Hz), 8.03–8.05 (m, 1H), 7.83–7.86 (m, 1H), 7.79 (d, 1H, <ce:italic>J</ce:italic> = 4.8 Hz), 7.68–7.70 (m, 1H), 7.63 (d, 1H, <ce:italic>J</ce:italic> = 7.8 Hz), 7.57 (d, 1H, <ce:italic>J</ce:italic> = 7.2 Hz), 7.04 (d, 1H, <ce:italic>J</ce:italic> = 7.2 Hz). <ce:sup loc="pre">13</ce:sup>C NMR (150 MHz, acetone-<ce:italic>d</ce:italic>
                           <ce:inf loc="post">6</ce:inf>) <ce:italic>δ</ce:italic> 166.7, 151.0, 149.7, 142.4, 139.1, 133.1, 131.6, 130.7, 128.5, 127.7, 127.2, 126.3, 125.1, 124.8, 124.7, 120.0, 113.3, 113.2. HRMS (ESI) calcd for C<ce:inf loc="post">18</ce:inf>H<ce:inf loc="post">13</ce:inf>N<ce:inf loc="post">2</ce:inf>O<ce:inf loc="post">3</ce:inf>S 337.0641 (M + H)<ce:sup loc="post">+</ce:sup>, found 337.0646.</ce:para>
                     </ce:section>
                  </ce:section>
                  <ce:section id="sec4.2" view="all">
                     <ce:label>4.2</ce:label>
                     <ce:section-title>Biology</ce:section-title>
                     <ce:section id="sec4.2.1" view="all">
                        <ce:label>4.2.1</ce:label>
                        <ce:section-title>
                           <ce:italic>In vitro</ce:italic> determination of effects of synthesized compounds on cancer cell proliferation</ce:section-title>
                        <ce:para id="p0140" view="all">Cancer cells (breast cancer cell lines MCF-7 and MDA-MB-231, pancreatic cancer cell lines AsPC-1 and Panc-1) were seeded in 96-well plates at a density of 2 × 10<ce:sup loc="post">3</ce:sup> cells/well and treated with DMSO, 0.01, 0.1, 1, 5, 10, and 100 μM of individual STAT3 inhibitors for 72 h. Proliferation was measured by treating cells with the (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sul-fophenyl)-2<ce:italic>H</ce:italic>-tetrazolium) (MTS) in a CellTiter 96t Aqueous Non-Radioactive Cell Proliferation Assay kit (Promega, Madison, WI, USA). Absorbance of all wells was determined by measuring OD at 550 nm after 1 h incubation at 37 °C on a 96-well iMark™ Microplate Absorbance Reader (BioRad, Hercules, CA). Each individual compound was tested in quadruplicate wells for each concentration.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.2.2" view="all">
                        <ce:label>4.2.2</ce:label>
                        <ce:section-title>Molecular docking studies</ce:section-title>
                        <ce:para id="p0145" view="all">Compound <ce:bold>5</ce:bold> was docked with the STAT3–SH2 domain using the X-ray structure (PDB code: <ce:inter-ref xlink:href="pdb:1BG1" xlink:type="simple">1BG1</ce:inter-ref>) and AutoDock Vina 1.1.2. Water molecules within the crystal structure were removed and polar hydrogens were added using AutoDockTools. The protein was treated as rigid. Docking runs were carried out using the standard parameters of the program for interactive growing and subsequent scoring, except for the parameters for setting grid box dimensions and center. For all of the docking studies, a grid box size of 30 Å × 30 Å × 30 Å, centered at coordinates 100.452 (<ce:italic>x</ce:italic>), 75.972 (<ce:italic>y</ce:italic>), and 68.790 (<ce:italic>z</ce:italic>) of the PDB structure.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.2.3" view="all">
                        <ce:label>4.2.3</ce:label>
                        <ce:section-title>Transient transfection and dual luciferase reporter assays</ce:section-title>
                        <ce:para id="p0150" view="all">MDA-MB-231 cells were seeded in 24-well plate at a density of 5 × 10<ce:sup loc="post">4</ce:sup> cells/well in RPMI-1640 medium containing 10% FBS and 1% penicillin–streptomycin. Transient transfections were performed 4 h after plating, using the method described previously <ce:cross-refs refid="bib40 bib51">[40,51]</ce:cross-refs>. Total amount of DNA for transfections was 0.5 μg/well, including pSTAT3-Luc (95%, obtained from Panomics, Cat# LR0077) and internal control vector renilla (5%, from Promega, Madison, WI, USA). 5 h after transfection, the cells were treated with compound <ce:bold>5</ce:bold> for 24 h, then reporter activity was evaluated using dual luciferase reporter assay kit (Promega, Madison, WI, USA) on an Omega™ Microplate Luminometer (BMG LABTECH Inc., NC, USA). Relative luciferase units were the ratio of the absolute activity of firefly luciferase to that of renilla luciferase. Experiments were conducted with triplicates and results are representatives of at least 3 independent experiments.</ce:para>
                     </ce:section>
                     <ce:section id="sec4.2.4" view="all">
                        <ce:label>4.2.4</ce:label>
                        <ce:section-title>Western blot analysis</ce:section-title>
                        <ce:para id="p0155" view="all">Protein levels were determined by Western blot using the previously described methods <ce:cross-ref refid="bib51">[51]</ce:cross-ref>. Total cell lysates were prepared from MDA-MB-231 cells. Protein concentrations were measured using the BCA Protein Assay Reagent (Pierce, Rockford, IL, USA). Equal amounts of total cellular protein extract (40 μg) were resuspended in denaturing sample loading buffer (0.5 M Tris–HCl, pH 6.8, 10% SDS, 0.1% bromophenol blue, and 20% glycerol), separated by electrophoresis on a 10% polyacrylamide SDS-PAGE gel and then electrophoretically transferred to a nitrocellulose membrane (Thermo Scientific, IL, USA) at 100 V for 1 h at 4 °C. The membrane was then incubated in a blocking solution containing 5% non-fat milk and 1% Tween 20 in TBS for 1 h. The membrane was then incubated with antibodies specific for: phospho-STAT3-pY705 (1:3000, Epitomics, #2236-1), STAT3 (1:2000, Cell Signaling, #4904), Caspase-3-cleaved (1:2000, Epitomics, #1476-1), Cyclin D1 (1:10,000, Epitomics, #2261-1) and β-actin (1:10,000, Sigma, clone AC-15). An anti-rabbit or anti-mouse secondary antibody (Amersham, Piscataway, NJ) was used at 1:4000 dilution. The Western blotted bands were visualized using ECL procedure according to the manufacturer's instructions (Amersham).</ce:para>
                     </ce:section>
                     <ce:section id="sec4.2.5" view="all">
                        <ce:label>4.2.5</ce:label>
                        <ce:section-title>
                           <ce:italic>In vivo</ce:italic> antitumor activity assays</ce:section-title>
                        <ce:para id="p0160" view="all">All procedures including mice and <ce:italic>in vivo</ce:italic> experiments were approved by the Institutional Animal Care and Use Committee (IACUC) of UT M.D. Anderson Cancer Center (MDACC). Female nude mice were obtained from MDACC and were used for orthotopic tumor studies at 4–6 weeks of age. The mice were maintained in a barrier unit with 12 h light–dark switch. Freshly harvested MDA-MB-231 cells (2.5 × 10<ce:sup loc="post">6</ce:sup> cells per mouse, resuspended in 100 μL PBS) were injected into the 3rd mammary fat pad of the mice, and then randomly assigned into 2 groups (6–7 mice per group). The mice were given 50 mg/kg compound <ce:bold>5</ce:bold> or vehicle five days per week when the tumor volume reached 200 mm<ce:sup loc="post">3</ce:sup>. All drugs were dissolved in 50% DMSO with 50% polyethylene glycol for <ce:italic>in vivo</ce:italic> administration. Body weights and tumors volume were measured daily and tumor volume was calculated according to the formula V = 0.5 × L × W<ce:sup loc="post">2</ce:sup>, where L = length (mm) and W = width (mm).</ce:para>
                     </ce:section>
                     <ce:section id="sec4.2.6" view="all">
                        <ce:label>4.2.6</ce:label>
                        <ce:section-title>Statistical analysis</ce:section-title>
                        <ce:para id="p0165" view="all">Statistical significance was determined using student <ce:italic>t</ce:italic>-test in cell cycle analysis. *Represents a <ce:italic>p</ce:italic> value less than 0.05.</ce:para>
                     </ce:section>
                  </ce:section>
               </ce:section>
               <ce:section id="sec5" view="all">
                  <ce:section-title>Conflict of interest</ce:section-title>
                  <ce:para id="p0170" view="all">None.</ce:para>
               </ce:section>
            </ce:sections>
            <ce:acknowledgment>
               <ce:section-title>Acknowledgments</ce:section-title>
               <ce:para id="p0175" view="all">This work was supported by grants <ce:grant-number refid="gs1">P50 CA097007</ce:grant-number>, <ce:grant-number refid="gs1">P30DA028821</ce:grant-number>, <ce:grant-number refid="gs1">R21MH093844</ce:grant-number> (J.Z.) from the <ce:grant-sponsor id="gs1" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">National Institute of Health</ce:grant-sponsor>, <ce:grant-sponsor id="gs2" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">R.A. Welch Foundation Chemistry and Biology Collaborative Grant</ce:grant-sponsor> from Gulf Coast Consortia (GCC) for Chemical Genomics, <ce:grant-sponsor id="gs3" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">John Sealy Memorial Endowment Fund</ce:grant-sponsor> (JZ), the <ce:grant-sponsor id="gs4" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">Duncan Family Institute (DFI) Seed Funding Program</ce:grant-sponsor>, and startup fund from <ce:grant-sponsor id="gs5" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">MD Anderson Cancer Center</ce:grant-sponsor> (QS). We thank Dr. Tianzhi Wang at the NMR core facility of UTMB for the NMR spectroscopy assistance.</ce:para>
            </ce:acknowledgment>
            <ce:appendices view="all">
               <ce:section id="appsec1" view="extended">
                  <ce:label>Appendix A</ce:label>
                  <ce:section-title>Supplementary data</ce:section-title>
                  <ce:para id="p0180" view="all">
                     <ce:display>
                        <ce:e-component id="ec1">
                           <ce:caption>
                              <ce:simple-para id="espara0010" view="all">Physicochemical parameters of selected novel STAT3 inhibitors, supplemental biological data, methods of biological evaluation and <ce:sup loc="pre">1</ce:sup>H and <ce:sup loc="pre">13</ce:sup>C NMR spectra for the compounds described in this paper.</ce:simple-para>
                           </ce:caption>
                           <ce:link locator="mmc1"/></ce:link>
                        </ce:e-component>
                     </ce:display>
                  </ce:para>
               </ce:section>
               <ce:section id="appsec2" view="compact-standard">
                  <ce:label>Appendix A</ce:label>
                  <ce:section-title>Supplementary data</ce:section-title>
                  <ce:para id="p0185" view="all">Supplementary data related to this article can be found at <ce:inter-ref xlink:href="doi:10.1016/j.ejmech.2013.01.023" xlink:type="simple">http://dx.doi.org/10.1016/j.ejmech.2013.01.023</ce:inter-ref>.</ce:para>
               </ce:section>
            </ce:appendices>
         </body>
         <tail view="all">
            <ce:bibliography id="cebib0010" view="all">
               <ce:section-title>References</ce:section-title>
               <ce:bibliography-sec id="cebibsec0010">
                  <ce:bib-reference id="bib1">
                     <ce:label>[1]</ce:label>
                     <sb:reference id="sref1">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Zhong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Wen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.E.</ce:given-name>
                                 <ce:surname>Darnell</ce:surname>
                                 <ce:suffix>Jr.</ce:suffix>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Science</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>264</sb:volume-nr>
                              </sb:series>
                              <sb:date>1994</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>95</sb:first-page>
                              <sb:last-page>98</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib2">
                     <ce:label>[2]</ce:label>
                     <sb:reference id="sref2">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.E.</ce:given-name>
                                 <ce:surname>Darnell</ce:surname>
                                 <ce:suffix>Jr.</ce:suffix>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>STATs and gene regulation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Science</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>277</sb:volume-nr>
                              </sb:series>
                              <sb:date>1997</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1630</sb:first-page>
                              <sb:last-page>1635</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib3">
                     <ce:label>[3]</ce:label>
                     <sb:reference id="sref3">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.F.</ce:given-name>
                                 <ce:surname>Bromberg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.H.</ce:given-name>
                                 <ce:surname>Wrzeszczynska</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Devgan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.G.</ce:given-name>
                                 <ce:surname>Pestell</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Albanese</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.E.</ce:given-name>
                                 <ce:surname>Darnell</ce:surname>
                                 <ce:suffix>Jr.</ce:suffix>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>STAT3 as an oncogene</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>98</sb:volume-nr>
                              </sb:series>
                              <sb:date>1999</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>295</sb:first-page>
                              <sb:last-page>303</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib4">
                     <ce:label>[4]</ce:label>
                     <sb:reference id="sref4">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Bromberg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.E.</ce:given-name>
                                 <ce:surname>Darnell</ce:surname>
                                 <ce:suffix>Jr.</ce:suffix>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The role of STATs in transcriptional control and their impact on cellular function</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncogene</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>19</sb:volume-nr>
                              </sb:series>
                              <sb:date>2000</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2468</sb:first-page>
                              <sb:last-page>2473</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib5">
                     <ce:label>[5]</ce:label>
                     <sb:reference id="sref5">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Hirano</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Ishihara</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Hibi</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncogene</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>19</sb:volume-nr>
                              </sb:series>
                              <sb:date>2000</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2548</sb:first-page>
                              <sb:last-page>2556</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib6">
                     <ce:label>[6]</ce:label>
                     <sb:reference id="sref6">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Bowman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Garcia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Turkson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Jove</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>STATs in oncogenesis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncogene</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>19</sb:volume-nr>
                              </sb:series>
                              <sb:date>2000</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2474</sb:first-page>
                              <sb:last-page>2488</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib7">
                     <ce:label>[7]</ce:label>
                     <sb:reference id="sref7">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Turkson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Jove</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>STAT proteins: novel molecular targets for cancer drug discovery</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncogene</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>19</sb:volume-nr>
                              </sb:series>
                              <sb:date>2000</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>6613</sb:first-page>
                              <sb:last-page>6626</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib8">
                     <ce:label>[8]</ce:label>
                     <sb:reference id="sref8">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.A.</ce:given-name>
                                 <ce:surname>Johnston</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.R.</ce:given-name>
                                 <ce:surname>Grandis</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>STAT3 signaling: anticancer strategies and challenges</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Interventions</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>11</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>18</sb:first-page>
                              <sb:last-page>26</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib9">
                     <ce:label>[9]</ce:label>
                     <sb:reference id="sref9">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Buettner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.B.</ce:given-name>
                                 <ce:surname>Mora</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Jove</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin. Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>8</sb:volume-nr>
                              </sb:series>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>945</sb:first-page>
                              <sb:last-page>954</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib10">
                     <ce:label>[10]</ce:label>
                     <sb:reference id="sref10">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.B.</ce:given-name>
                                 <ce:surname>Haura</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Turkson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Jove</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Mechanisms of disease: insights into the emerging role of signal transducers and activators of transcription in cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Clin. Pract. Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>2</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>315</sb:first-page>
                              <sb:last-page>324</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib11">
                     <ce:label>[11]</ce:label>
                     <sb:reference id="sref11">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Kortylewski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Pardoll</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Immunol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>7</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>41</sb:first-page>
                              <sb:last-page>51</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib12">
                     <ce:label>[12]</ce:label>
                     <sb:reference id="sref12">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Jove</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The STATs of cancer—new molecular targets come of age</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Cancer</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>4</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>97</sb:first-page>
                              <sb:last-page>105</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib13">
                     <ce:label>[13]</ce:label>
                     <sb:reference id="sref13">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.E.</ce:given-name>
                                 <ce:surname>Darnell</ce:surname>
                                 <ce:suffix>Jr.</ce:suffix>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Validating Stat3 in cancer therapy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Med.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>11</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>595</sb:first-page>
                              <sb:last-page>596</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib14">
                     <ce:label>[14]</ce:label>
                     <sb:reference id="sref14">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.E.</ce:given-name>
                                 <ce:surname>Darnell</ce:surname>
                                 <ce:suffix>Jr.</ce:suffix>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Transcription factors as targets for cancer therapy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Cancer</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>2</sb:volume-nr>
                              </sb:series>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>740</sb:first-page>
                              <sb:last-page>749</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib15">
                     <ce:label>[15]</ce:label>
                     <sb:reference id="sref15">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Pardoll</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Jove</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>STATs in cancer inflammation and immunity: a leading role for STAT3</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Cancer</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>9</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>798</sb:first-page>
                              <sb:last-page>809</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib16">
                     <ce:label>[16]</ce:label>
                     <sb:reference id="sref16">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Germain</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.A.</ce:given-name>
                                 <ce:surname>Frank</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Targeting the cytoplasmic and nuclear functions of signal transducers and activators of transcription 3 for cancer therapy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin. Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>13</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5665</sb:first-page>
                              <sb:last-page>5669</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib17">
                     <ce:label>[17]</ce:label>
                     <sb:reference id="sref17">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Costantino</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Barlocco</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>STAT3 as a target for cancer drug discovery</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>15</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>834</sb:first-page>
                              <sb:last-page>843</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib18">
                     <ce:label>[18]</ce:label>
                     <sb:reference id="sref18">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Siddiquee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Turkson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>STAT3 as a target for inducing apoptosis in solid and hematological tumors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell. Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>18</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>254</sb:first-page>
                              <sb:last-page>267</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib19">
                     <ce:label>[19]</ce:label>
                     <sb:reference id="sref19">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.W.</ce:given-name>
                                 <ce:surname>Schindler</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Series introduction. JAK-STAT signaling in human disease</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Clin. Invest.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>109</sb:volume-nr>
                              </sb:series>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1133</sb:first-page>
                              <sb:last-page>1137</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib20">
                     <ce:label>[20]</ce:label>
                     <sb:reference id="sref20">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Turkson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Ryan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Haura</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Laudano</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Sebti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.D.</ce:given-name>
                                 <ce:surname>Hamilton</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Jove</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Biol. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>276</sb:volume-nr>
                              </sb:series>
                              <sb:date>2001</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>45443</sb:first-page>
                              <sb:last-page>45455</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib21">
                     <ce:label>[21]</ce:label>
                     <sb:reference id="sref21">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Matsuno</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Masuda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Uehara</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Sato</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Muroya</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Takahashi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Yokotagawa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Furuya</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Okawara</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Otsuka</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Ogo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Ashizawa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Oshita</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Tai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Ishii</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Akiyama</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Asai</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Identification of a new series of STAT3 inhibitors by virtual screening</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ACS Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>1</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>371</sb:first-page>
                              <sb:last-page>375</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib22">
                     <ce:label>[22]</ce:label>
                     <sb:reference id="sref22">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Siddiquee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.C.</ce:given-name>
                                 <ce:surname>Guida</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Blaskovich</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Greedy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.R.</ce:given-name>
                                 <ce:surname>Lawrence</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.L.</ce:given-name>
                                 <ce:surname>Yip</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Jove</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.M.</ce:given-name>
                                 <ce:surname>McLaughlin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.J.</ce:given-name>
                                 <ce:surname>Lawrence</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.M.</ce:given-name>
                                 <ce:surname>Sebti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Turkson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proc. Natl. Acad. Sci. U. S. A.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>104</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>7391</sb:first-page>
                              <sb:last-page>7396</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib23">
                     <ce:label>[23]</ce:label>
                     <sb:reference id="sref23">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Schust</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Sperl</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Hollis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.U.</ce:given-name>
                                 <ce:surname>Mayer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Berg</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Stattic: a small-molecule inhibitor of STAT3 activation and dimerization</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Chem. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>13</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1235</sb:first-page>
                              <sb:last-page>1242</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib24">
                     <ce:label>[24]</ce:label>
                     <sb:reference id="sref24">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Turkson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Palmer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Kay</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Stanko</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.B.</ce:given-name>
                                 <ce:surname>Mora</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Sebti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Jove</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Inhibition of constitutive signal transducer and activator of transcription 3 activation by novel platinum complexes with potent antitumor activity</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Cancer Ther.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>3</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1533</sb:first-page>
                              <sb:last-page>1542</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib25">
                     <ce:label>[25]</ce:label>
                     <sb:reference id="sref25">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Turkson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.B.</ce:given-name>
                                 <ce:surname>Mora</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Burns</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Sebti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Jove</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A novel platinum compound inhibits constitutive Stat3 signaling and induces cell cycle arrest and apoptosis of malignant cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Biol. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>280</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>32979</sb:first-page>
                              <sb:last-page>32988</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib26">
                     <ce:label>[26]</ce:label>
                     <sb:reference id="sref26">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Ren</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Duan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>He</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Pan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Pei</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Ding</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Identification of niclosamide as a new small-molecule inhibitor of the STAT3 signaling pathway</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ACS Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>1</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>454</sb:first-page>
                              <sb:last-page>459</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib27">
                     <ce:label>[27]</ce:label>
                     <sb:reference id="sref27">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Horiguchi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Asano</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Kuroda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Sato</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Asakuma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Ito</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Hayakawa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Sumitomo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Asano</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Br. J. Cancer</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>102</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1592</sb:first-page>
                              <sb:last-page>1599</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib28">
                     <ce:label>[28]</ce:label>
                     <sb:reference id="sref28">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Iwamaru</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Szymanski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Iwado</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Aoki</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Yokoyama</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Fokt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Hess</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Conrad</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Madden</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Sawaya</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Kondo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Priebe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Kondo</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncogene</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>26</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2435</sb:first-page>
                              <sb:last-page>2444</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib29">
                     <ce:label>[29]</ce:label>
                     <sb:reference id="sref29">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Bai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Bernard</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Nikolovska-Coleska</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Gomez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Yi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Structure-based design of conformationally constrained, cell-permeable STAT3 inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ACS Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>1</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>85</sb:first-page>
                              <sb:last-page>89</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib30">
                     <ce:label>[30]</ce:label>
                     <sb:reference id="sref30">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.K.</ce:given-name>
                                 <ce:surname>Mandal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Ren</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Xiong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>McMurray</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Structure–affinity relationships of glutamine mimics incorporated into phosphopeptides targeted to the SH2 domain of signal transducer and activator of transcription 3</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>52</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>6126</sb:first-page>
                              <sb:last-page>6141</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib31">
                     <ce:label>[31]</ce:label>
                     <sb:reference id="sref31">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.K.</ce:given-name>
                                 <ce:surname>Mandal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Gao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Lu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Ren</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Ramesh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>Birtwistle</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.K.</ce:given-name>
                                 <ce:surname>Kaluarachchi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.C.</ce:given-name>
                                 <ce:surname>Bast</ce:surname>
                                 <ce:suffix>Jr.</ce:suffix>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.S.</ce:given-name>
                                 <ce:surname>Liao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>McMurray</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Potent and selective phosphopeptide mimetic prodrugs targeted to the Src homology 2 (SH2) domain of signal transducer and activator of transcription 3</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>54</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3549</sb:first-page>
                              <sb:last-page>3563</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib32">
                     <ce:label>[32]</ce:label>
                     <sb:reference id="sref32">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Yue</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Turkson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Targeting STAT3 in cancer: how successful are we?</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Expert Opin. Investig. Drugs</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>18</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>45</sb:first-page>
                              <sb:last-page>56</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib33">
                     <ce:label>[33]</ce:label>
                     <sb:reference id="sref33">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Deng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Grande</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Neamati</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Small molecule inhibitors of stat3 signaling pathway</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Cancer Drug Targets</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>7</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>91</sb:first-page>
                              <sb:last-page>107</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib34">
                     <ce:label>[34]</ce:label>
                     <sb:reference id="sref34">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Jiang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.H.</ce:given-name>
                                 <ce:surname>Gao</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Small molecule inhibitors of STAT3 for cancer therapy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>18</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4012</sb:first-page>
                              <sb:last-page>4018</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib35">
                     <ce:label>[35]</ce:label>
                     <sb:reference id="sref35">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.K.</ce:given-name>
                                 <ce:surname>Mankan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.R.</ce:given-name>
                                 <ce:surname>Greten</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Inhibiting signal transducer and activator of transcription 3: rationality and rationale design of inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Expert Opin. Invest. Drugs</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>20</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1263</sb:first-page>
                              <sb:last-page>1275</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib36">
                     <ce:label>[36]</ce:label>
                     <sb:reference id="sref36">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Lavecchia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Di Giovanni</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Novellino</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>STAT-3 inhibitors: state of the art and new horizons for cancer treatment</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>18</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2359</sb:first-page>
                              <sb:last-page>2375</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib37">
                     <ce:label>[37]</ce:label>
                     <sb:reference id="sref37">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.D.</ce:given-name>
                                 <ce:surname>Page</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.P.</ce:given-name>
                                 <ce:surname>Ball</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.T.</ce:given-name>
                                 <ce:surname>Gunning</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Signal transducer and activator of transcription 3 inhibitors: a patent review</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Expert Opin. Ther. Pat.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>21</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>65</sb:first-page>
                              <sb:last-page>83</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib38">
                     <ce:label>[38]</ce:label>
                     <sb:reference id="sref38">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Debnath</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Neamati</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Small molecule inhibitors of signal transducer and activator of transcription 3 (Stat3) protein</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>55</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>6645</sb:first-page>
                              <sb:last-page>6668</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib39">
                     <ce:label>[39]</ce:label>
                     <sb:reference id="sref39">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.A.</ce:given-name>
                                 <ce:surname>Erlanson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.S.</ce:given-name>
                                 <ce:surname>McDowell</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>O'Brien</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Fragment-based drug discovery</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>47</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3463</sb:first-page>
                              <sb:last-page>3482</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib40">
                     <ce:label>[40]</ce:label>
                     <sb:reference id="sref40">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.C.</ce:given-name>
                                 <ce:surname>Rees</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Congreve</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.W.</ce:given-name>
                                 <ce:surname>Murray</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Carr</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Fragment-based lead discovery</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Drug Discov.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>3</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>660</sb:first-page>
                              <sb:last-page>672</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib41">
                     <ce:label>[41]</ce:label>
                     <sb:reference id="sref41">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.J.</ce:given-name>
                                 <ce:surname>Hajduk</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Fragment-based drug design: how big is too big?</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>49</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>6972</sb:first-page>
                              <sb:last-page>6976</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib42">
                     <ce:label>[42]</ce:label>
                     <sb:reference id="sref42">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Babaoglu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.K.</ce:given-name>
                                 <ce:surname>Shoichet</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Deconstructing fragment-based inhibitor discovery</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Chem. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>2</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>720</sb:first-page>
                              <sb:last-page>723</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib43">
                     <ce:label>[43]</ce:label>
                     <sb:reference id="bib43a">
                        <ce:label>(a)</ce:label>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.J.</ce:given-name>
                                 <ce:surname>Hajduk</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Greer</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A decade of fragment-based drug design: strategic advances and lessons learned</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Drug Discov.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>6</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>211</sb:first-page>
                              <sb:last-page>219</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <sb:reference id="bib43b">
                        <ce:label>(b)</ce:label>
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Barelier</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Krimm</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Ligand specificity, privileged substructures and protein druggability from fragment-based screening</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Opin. Chem. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>15</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>469</sb:first-page>
                              <sb:last-page>474</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib44">
                     <ce:label>[44]</ce:label>
                     <sb:reference id="sref43">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Jou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Fragment-based drug design and drug repositioning using multiple ligand simultaneous docking (MLSD): identifying celecoxib and template compounds as novel inhibitors of signal transducer and activator of transcription 3 (STAT3)</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>54</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5592</sb:first-page>
                              <sb:last-page>5596</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib45">
                     <ce:label>[45]</ce:label>
                     <sb:reference id="sref44">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Song</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proc. Natl. Acad. Sci. U. S. A.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>102</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4700</sb:first-page>
                              <sb:last-page>4705</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib46">
                     <ce:label>[46]</ce:label>
                     <sb:reference id="sref45">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Becker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Groner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.W.</ce:given-name>
                                 <ce:surname>Muller</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Three-dimensional structure of the Stat3Beta homodimer bound to DNA</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nature</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>394</sb:volume-nr>
                              </sb:series>
                              <sb:date>1998</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>145</sb:first-page>
                              <sb:last-page>151</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib47">
                     <ce:label>[47]</ce:label>
                     <sb:reference id="sref46">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Trott</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.J.</ce:given-name>
                                 <ce:surname>Olson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Comput. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>31</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>455</sb:first-page>
                              <sb:last-page>461</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib48">
                     <ce:label>[48]</ce:label>
                     <sb:reference id="sref47">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Catlett-Falcone</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.H.</ce:given-name>
                                 <ce:surname>Landowski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.M.</ce:given-name>
                                 <ce:surname>Oshiro</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Turkson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Levitzki</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Savino</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Ciliberto</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Moscinski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.L.</ce:given-name>
                                 <ce:surname>Fernández-Luna</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Nuñez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.S.</ce:given-name>
                                 <ce:surname>Dalton</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Jove</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Immunity</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>10</sb:volume-nr>
                              </sb:series>
                              <sb:date>1999</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>105</sb:first-page>
                              <sb:last-page>115</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib49">
                     <ce:label>[49]</ce:label>
                     <sb:reference id="sref48">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Bromberg</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Stat proteins and oncogenesis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Clin. Invest.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>109</sb:volume-nr>
                              </sb:series>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1139</sb:first-page>
                              <sb:last-page>1142</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib50">
                     <ce:label>[50]</ce:label>
                     <sb:reference id="sref49">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Yue</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.D.</ce:given-name>
                                 <ce:surname>Page</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.T.</ce:given-name>
                                 <ce:surname>Namanja</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Paladino</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.T.</ce:given-name>
                                 <ce:surname>Gunning</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Turkson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proc. Natl. Acad. Sci. U. S. A.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>109</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>9623</sb:first-page>
                              <sb:last-page>9628</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib51">
                     <ce:label>[51]</ce:label>
                     <sb:reference id="sref50">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Shen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.P.</ce:given-name>
                                 <ce:surname>Uray</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.I.</ce:given-name>
                                 <ce:surname>Krisko</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.E.</ce:given-name>
                                 <ce:surname>Strecker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.T.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.H.</ce:given-name>
                                 <ce:surname>Brown</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The AP-1 transcription factor regulates breast cancer cell growth via cyclins and E2F factors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncogene</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>27</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>366</sb:first-page>
                              <sb:last-page>377</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                  </ce:bib-reference>
               </ce:bibliography-sec>
            </ce:bibliography>
         </tail>
      </article>
   </xocs:serial-item></xocs:doc></originaltext></full-text-retrieval-response>